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Squamous cell carcinoma of the oesophagus (OSCC) is a common malignancy that 
occurs with high frequency in certain parts of the world, including South Africa. The 
aetiology of OSCC has remained unclear although many studies suggest that it is caused 
by a combination of variable risk factors. Recent reports implicate a variety of genetic 
factors in the carcinogenesis of OSCC but their involvement is yet to be defined.  
 
The aim of this study was to examine in oesophageal tumour samples, the relative 
expression of the genes for vascular endothelial growth factor (VEGF), human epidermal 
growth factor receptor 1 and 2 (HER1 and HER2) and matrix metalloproteinase 2 
(MMP2), all of which have been implicated in carcinogenesis.  
 
A novel universal probe library (UPL) system and real time PCR technology was used to 
detect gene expression. The relative expression of the four genes was standardized using 
the gene for a non-regulated reference protein, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). The UPL detection system with real time PCR was compared 
to the conventional SYBR Green I system, based on VEGF expression. Quantification of 
real time PCR was evaluated by two methods, namely the standard curve method and the 
Pfaffl model, which is based on PCR efficiencies. Two groups of patients were analysed 
in this study following a retrospective histological assessment of sampling methods, 
which demonstrated the discordant classification of eight sample pairs. Group A 
comprised the original 30 patient cohort while Group B comprised the resulting 22 
patient cohort after the removal of discordant sample pairs.  
 v 
Evaluation of mRNA gene expression using the standard curve method combined with 
either the UPL system or the SYBR Green I system deduced that all four genes studied 
were upregulated in oesophageal tumours. Upregulation of VEGF in sample groups A 
and B was by factors of 3.6 (A) and 4 (B) using the UPL system, and by factors of 3 (A; 
p = 0.001) and 4 (B; p = 0.001) using SYBR Green I. The HER1 gene was upregulated by 
a factor of 2.9 in both A and B groups (p = 0.003), the HER2 gene by factors of 2.6 (A) 
and 1.9 (B), and the MMP2 gene by a factor of 1.7 (both A and B), all using the UPL 
system. Assessment using the Pfaffl model combined with either the UPL or SYBR 
Green I system showed upregulation of all genes by the following factors: 2.8 in group A 
(p = 0.001) and 3.4 in group B (p = 0.001) for VEGF (UPL), 4.8 (A) and 6.6 (B) for 
VEGF (SYBR Green I), 3.2 (A; p = 0.001) and 4.0 (B) for HER1 (UPL), 3.6 (A; p = 
0.001) and 4.0 (B) for HER2 (UPL), and finally 1.4 (A; p = 0.001) and 1.1 (B; p = 0.001) 
for MMP2 (UPL).  
 
Correlation analyses of mRNA expression of the VEGF, HER1 and MMP2 genes in 
oesophageal tumours showed strong gene inter-relationship associations: 79.8% for 
VEGF and MMP2, 86.4% for HER1 and VEGF, and 88.8% for HER1 and MMP2.  With 
respect to clinical features, overexpression of VEGF was related to gender (group A, p = 
0.012; group B, p = 0.044) and race (p = 0.044), as well as an increased depth of tumour 
invasion (p = 0.046). Overexpression of HER2 was also related to race (p = 0.015), while 
overexpression of the MMP2 gene was related to patients that did not have lymphatic 
node metastasis (p = 0.030). Furthermore, a larger tumour size was associated with an 
increased mitotic rate (p = 0.043) and increased necrosis (p = 0.043). Anaplasia was 
 vi 
associated with an increased depth of tumour invasion (p =0.015) while perineurial 
invasion was influenced by gender (p = 0.041).  
 
It was concluded that the UPL system using real time PCR technology is a robust and 
reliable method for the detection of gene expression. The UPL system and SYBR Green I 
system demonstrated similar detection abilities, but the UPL system showed equal or 
better performance and specificity compared with the SYBR Green I system. The Pfaffl 
model was found to combine simple, precise ease of performance with the production of 
rapid and reliable results. The overexpression of VEGF, HER1, HER2 and MMP2 genes 
in oesophageal tumours implicates a possible role in both the tumourigenesis of OSCC 
and the pathophysiology of tumour growth and spread. The positive correlations between 
clinicopathological factors, such as gender and race, to gene expression suggest a multi-
factorial aetiology of OSCC. Further large scale and in-depth gene expression studies, 
combined with clinicopathological analyses are necessary for a better understanding of 
OSCC carcinogenesis. The identification of prognostic biomarkers and novel therapeutic 
targets may ultimately lead to improved diagnosis, treatment and prognosis of OSCC. 
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Chapter 1: Literature review 
 
1.1 Oesophageal cancer 
Worldwide, oesophageal cancer is the eighth most common cancer and occurs as two main 
aetiologically unrelated subtypes, namely, oesophageal squamous cell carcinoma (OSCC) and 
adenocarcinoma (World Health Organisation, 1997). Adenocarcinoma is more common in 
developed countries and is primarily associated with gastric reflux and Barrett’s oesophagus. 
In contrast, OSCC is generally more prevalent in developing countries and is associated 
mainly with smoking, alcohol consumption and other factors (World Health Organisation, 
1997). Variations in the incidence and aetiological features of OSCC suggest that specific 
environmental, geographical and lifestyle risk factors may play an important role in the 
aetiology of OSCC. 
 
1.1.1 Epidemiology and Trends 
1.1.1.1 Geographical 
The incidence of OSCC shows distinct variations in its geographical distribution. It occurs at 
very high frequencies in areas such as the Linxian district in China, parts of Iraq and Iran, 
particular regions in South Africa, South America, East and Central Africa (Lam, 2000; Yang, 
1980; Sitas, 1992). Endemic regions for OSCC are those that display a high incidence of the 
disease relative to other parts of the world with as much as a 500-fold difference in incidence 




Prior to the 1950s, OSCC was rarely reported in South Africa (Isaacson, 1982). Thereafter, 
studies reported an increase in the number of oesophageal cancer cases diagnosed in the Black 
population, including the Zulu people of the Natal region (now KwaZulu-Natal) (Dlamini and 
Bhoola, 2005; Higginson and Oettle, 1960; Isaacson, 1982; Schonland and Bradshaw, 1969). 
The Transkei region in South Africa is often seen as the epicenter of OSCC in Africa and has 
one of the highest incidences in the world (357.2 per 100,000 for people aged between 35 and 
64) (Doll, 1969). The disease has now reached epidemic proportions in the Transkei and 
Ciskei regions of South Africa, presenting a serious health burden to the country (Sammon, 
2007). Oesophageal squamous cell carcinoma is predominantly diagnosed in urban 
populations of the western world, but in China, Iran and South Africa it is mainly found in the 
rural population suggesting evidence of a socio-economic bias in poorer countries (Rose, 
1973). This may be due to dietary, lifestyle and environmental risk factors that are common to 
these subpopulations. 
 
1.1.1.2 Race and Gender 
Oesophageal squamous cell carcinoma demonstrates distinct ethnic variations, with Black 
populations having a higher incidence of the disease compared with Caucasians. Numerous 
cultural and lifestyle factors have been attributed to these differences but the underlying cause 
is not clear (Duranceau et al., 1998). Gender also impacts on the incidence of OSCC.  Men 
have a higher incidence of the disease compared to women. The worldwide incidence, per 
100,000 population, lies between 2.5 and 5.0 for men and 1.5 and 2.5 for women (Parkin et al., 
1988). In South Africa, OSCC is the most commonly occurring cancer in Black males and the 




The aetiology of oesophageal cancer remains unclear. Evidence suggests that OSCC has a 
multi-factorial aetiology arising from a combination of associated risk factors (Blot, 1994).  
These risk factors are briefly discussed below. 
 
1.1.3 Risk factors 
1.1.3.1 Tobacco 
Tobacco is a well recognised oesophageal carcinogen when used in any form e.g. cigarettes, 
cigars, pipe tobacco, chewing tobacco and snuff.  Tobacco is associated with non-endemic 
oesophageal cancer worldwide, with the risk increasing in proportion to use (Yu et al., 1988). 
In endemic areas of South Africa, such as KwaZulu-Natal (KZN) and Transkei, studies have 
shown a significant association of tobacco usage, both duration and amount, with OSCC 
(Bradshaw and Schonland, 1969; Sammon, 1992; van Rensburg et al., 1985). Cigarette 
smokers are also reported to have a 5-10 fold higher risk for oesophageal cancer compared to 
non-smokers (Blot and Mclaughlin, 1999).  In the urban Black population of Soweto, South 
Africa, the relative risk of cigarette smoke for OSCC was found to be higher with the use of 
hand-rolled cigarettes in comparison to commercial cigarettes (Segal et al., 1988).  With 
cessation of smoking, the risk of OSCC has been shown to decrease substantially within 5-10 
years (Blot and Mclaughlin, 1999). Tobacco tars and cigarette smoke contain many chemical 
carcinogens including aromatic amines, haloethers, lactones, N-nitriso compounds, polycyclic 






Excessive use of alcohol has been observed as an independent risk factor for OSCC, with the 
highest risk being associated with consumption of spirits rather than wine or beer (Blot and 
Mclaughlin, 1999; Tuyns et al., 1979). Alcohol causes chronic irritation and inflammation to 
the oesophageal mucosa (Enzinger and Mayer, 2003). Alcohol consumption and tobacco 
smoking have been shown to have a synergistic effect on the risk of oesophageal cancer. It has 
been suggested that alcohol acts as a solvent for the carcinogens in tobacco smoke, enhancing 
the risk of developing the disease (Crew and Neugut, 2004).   
 
1.1.3.3 Diet and Nutrients 
As mentioned previously, oesophageal cancer is a disease associated with lower socio-
economic groups and it has been suggested that nutritional factors may play a role in the 
pathogenesis (Blot and Mclaughlin, 1999). Deficiencies in vitamins and trace minerals such as 
vitamin A, B12
 
, C, E, niacin, riboflavin, folic acid and zinc may increase the risk of OSCC,  
while diets rich in fresh fruit, raw vegetables and antioxidants are thought to be protective 
(Blot and Mclaughlin, 1999). Also, evidence suggests that a chronic low intake of 
micronutrients, together with an inadequate protein intake, increases the predisposition of the 
oesophageal epithelium to malignant transformation (Blot and Mclaughlin, 1999; Ribeiro et 
al., 1996). Throughout the world, in areas endemic for OSCC, maize and/or wheat comprise 
the dietary staples (van Rensburg, 1981). These diets are deficient in riboflavin, niacin, 
vitamin C and other micronutrients. Riboflavin deficiency has been implicated in the early 
stages of oesophageal cell proliferation and dysplasia (Muňoz et al., 1987).  
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Other dietary factors that are known risk factors for oesophageal cancer are salt pickled and 
salt cured foods such as pickled vegetables, smoked fish, cured meat and dried red chillies, all 
of which contain high concentrations of nitrosamines (Ribeiro et al, 1996). High doses of 
nitrosamines are known to be carcinogenic and extensive research in China has implicated 
nitrosamines and their precursors as probable aetiological factors in high incidence areas (Lu 
et al., 1991).  
 
1.1.3.4 Fungal Mycotoxins 
Fungi such as Fusarium verticillioides, Aspergillus, Penicillium, Cladosporium, Alternaria 
and Geotrichum Spp have been implicated as risk factors for OSCC as they have been shown 
to promote the formation of nitrosamines (Chang et al., 1992). Additionally, a molybdenum 
deficiency in the soil has been associated with an increased susceptibility of maize to a variety 
of fungal species such as Fusarium and Aspergillus (Chang et al., 1992). Epidemiologic 
studies in the high incidence regions of South Africa and China, have identified a strong 
association between the consumption of maize contaminated with Fusarium and the incidence 
of OSCC (Marasas, 2001; Yoshizawa et al., 1994).  
 
1.1.3.5 Human Papilloma Virus 
The human papilloma virus (HPV) has long been implicated as a risk factor for oesophageal 
cancer. In vitro and in vivo studies have confirmed the oncogenic properties of HPV types 16 
and 18. The proteins E6 and E7 produced by these viruses are oncoproteins that have the 
capacity to immortalise various human cell types, inactivate host proteins (such as p53 or 
pRb), and induce mutations in the host cell DNA (Caldeira et al., 2000; Mantovani and Banks, 
1999; zur Hausen, 1999).  
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Studies from high risk areas for OSCC have suggested a role of HPV in the aetiology of 
OSCC, whereas other studies from low risk areas have failed to find any association (Chang et 
al., 2000; Syrjänen, 2002). 
 
1.1.3.6 Associated diseases 
Several diseases such as the Plummer-Vinson syndrome, coeliac disease, scleroderma, tylosis, 
oesophageal diverticula and achalasia are thought to be risk factors for oesophageal cancer. 
Patients presenting with these conditions reportedly have a significantly increased risk of 
developing OSCC (Ferguson and Kingstone, 1996; Larsson et al., 1975; Marger and Marger, 
1993; Whitaker and Bishop, 1979). 
 
1.1.3.7 Genetic predisposition 
Tylosis is the only recognised familial syndrome that predisposes individuals to OSCC. It is a 
rare autosomal dominant disorder which confers up to a 95% risk of OSCC by the age of 70 
years (Marger and Marger, 1993). A higher risk of OSCC has however been observed among 
relatives of oesophageal cancer patients. This familial aggregation has been reported in several 
countries, including the high incidence regions in China (Chang-Claude et al., 1997). Ethnic 
differences in the frequency of OSCC suggest a genetic contribution but no specific genetic 
factor has yet been identified (Lam, 2000). Polymorphisms in several genes such as 
glutathione S-transferase (GST) and cytochrome P450 2E1 (CYP2E1) have been associated 
with an increased risk for OSCC. The CYP2E1 protein is involved in the metabolic activation 
of nitrosamines, and genetic variations may therefore contribute to early carcinogenic events 
of OSCC (Lin et al., 1998).  
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1.1.4 The Oesophagus: Structure and Function 
The oesophagus extends from the lower end of the pharynx to the stomach and is divided into 
three distinct anatomic portions: cervical, thoracic and abdominal (Damjanov and Linder, 
1996). It crosses the thorax through the posterior part of the mediastinum, behind the trachea 
and left main bronchus, through the left crus of the diaphragm and into the stomach 
(Damjanov and Linder, 1996). Structurally, the oesophagus is a hollow, tubular organ which is 
in a collapsed state most of the time although it distends to allow the passage of food and 
saliva, swallowing or regurgitation. The entrance of oesophagus is bordered by the crico-
pharyngeus muscle which acts as an upper oesophageal sphincter. This has a dual function, 
firstly to prevent regurgitation of gastric contents into the oesophagus and secondly to relax 
during swallowing to allow the passage of food (McGee et al., 1992).  The lower oesophageal 
sphincter aids in the role of swallowing and is located at the abdominal oesophagus. There are 
four distinct layers forming the walls of the oesophagus: the mucosa, submucosa, muscularis 
propria and a peri-oesophageal fibrous layer (Figure 1.1) (McGee et al., 1992,).  The four 









Figure 1.1 Histopathologic section of the normal oesophageal wall. Ep: epithelium, Lpm: lamina 
propria mucosae, Mm: muscularis mucosae, Sm: submucosa, MP: muscularis propria, Icm: inner 
circular muscle, Ct: intermuscular connective tissue, Olm: outer longitudinal muscle, Ad: adventitia 
layer. (Hematoxylin-Eosin (H&E) stain; original magnification, x 6.) Diagram modified from (Yamada 
et al., 2006). 
 
The first layer of the oesophageal wall is the epithelium layer (mucosa) which consists of pale 
stratified non-keratinizing squamous epithelim. Below the epithelium is the lamina propria 
that comprises loose connective tissue and overlies the muscularis mucosae consisting of a 
thin bundle of smooth muscle fibres (Damjanov and Linder, 1996). The submucosa contains a 
network of lymphatics, lymphocytes and blood vessels as well as mucus producing glands that 





The muscularis propria section consists of an inner circular and an outer longitudinal coat of 
smooth muscle, innervated by the vagus, glossopharyngeal nerve and sympathetic ganglia 
(McGee et al., 1992). The last layer of the oesophageal wall is the adventitia (serosa) that 
comprises loose connective tissue and blood vessels (Damjanov and Linder, 1996). 
 
1.1.5 Pathophysiology 
The majority of oesophageal tumours (>50%) arise in the middle third of the oesophagus, 
approximately a third occur in the lower oesophagus and the remainder appear in the upper 
oesophagus (Damjanov and Linder, 1996). Tumours are usually described as polyploid (60%), 
ulcerating (25%) or infiltrating (15%), although mixed patterns are common (Damjanov and 
Linder, 1996). Oesophageal tumours are categorised into four different types: superficial (type 
0), protruding (type 1), ulcerative and localised (type 2), ulcerative and infiltrative (type 3) 











A  B 
C  D 
 
Figure 1.2. Macroscopic images in four different types of oesophageal carcinoma are shown (A-D). A: 
Superficial and flat type (type 0–IIa-IIc). Arrows show an irregular thickening. B: Protruding type 
(type 1). C: Ulcerative and localised type (type 2). D: Ulcerative and infiltrative type (type 3) (Yamada 
et al., 2006). 
 
1.1.5.1 Differentiation of oesophageal tumours 
Differentiation of oesophageal tumour cells refers to the extent of resemblance, both 
morphologically and functionally, to cells of the tissue of origin. In comparison to normal 
cells, tumour cells display marked irregularity in their nuclei. Some of these differences 
include: irregularity in shape or form (pleomorphism), larger nuclei, prominent irregular 
nucleoli and numerous mitoses and atypical mitoses (Kumar et al, 2003). Oesophageal 
tumours are also classified microscopically as well, moderately or poorly differentiated 
(Figure 1.3). Most tumours are moderately differentiated but some display advanced 
differentiation, forming whorls of tumour cells known as “keratin pearls” (Damjanov and 
Linder, 1996).   
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Well differentiated tumours contain abundant amounts of keratin, have easily observed 
intercellular bridges and cell layers undergoing differentiation, whereas poorly differentiated 
tumours have little or no keratin, intercellular bridges or differentiation of cell layers. Tumour 
cells also usually fail to develop recognisable patterns of orientation to each other, that is, they 






Figure 1.3. Photomicrographs of oesophageal tumours. A. Well differentiated squamous cell 
carcinoma of the oesophagus with large areas of pink staining keratin. Small epithelial pearls are 
visible (arrow) B. Poorly differentiated squamous cell carcinoma of the oesophagus comprising 





1.1.5.2 Early oesophageal squamous cell carcinoma 
Oesophageal dysplasia is a precursor lesion of OSCC. It is typically encountered only in the 
epithelium and exhibits a loss of uniformity in individual cells, as well as a loss of 
architectural orientation. The presence of dysplasia in the squamous epithelium suggests 
potential for malignant transformation. Dysplastic cells may be seen in the mucosa adjacent to 
the tumour and display very similar characteristics to the cancerous cells with regards to 
pleiomorphism, hyperchromatic nuclei and frequent mitotic events. When dysplastic changes 
are marked and involve the entire thickness of the epithelium, the lesion is known as 
‘carcinoma in situ’, a pre-invasive stage of cancer (Kumar et al, 2003). Dysplasia does not 
necessarily progress to cancer although mild, moderate and severe dysplasia may precede 
carcinoma or may be associated with growth at presentation (McGee et al., 1992).  A follow 
up study of early asymptomatic patients with in situ carcinoma of the oesophagus revealed that 
3-4 years elapsed before the development of OSCC (Guanrei et al., 1982).  
 
1.1.5.3 Advanced oesophageal squamous cell carcinoma 
Oesophageal cancers are characterised by widespread local growth and lymph node 
involvement before dissemination. Malignant neoplasms disseminate by one of three 
pathways: seeding within body cavities, lymphatic spread or haematogenous spread. The 
submucosal segment of the oesophageal wall is rich in lymphatics that extend longitudinally 
as well as laterally. Therefore submucosal spread of the tumour is common. The longitudinal 
network of lymphatics allows frequent spread to the nodes in the neck, thorax and abdomen 
despite tumour location. Once a tumour has invaded muscular layers of the oesophagus, the 
incidence of positive regional lymph nodes exceeds 75% (Greene et al., 2002).  
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Widespread distant metastases are almost always present at the time of death in patients with 
OSCC (Mandard et al., 1981). Studies have shown that the length of the oesophagus invaded 
by the carcinoma is directly correlated with the extent of involvement of adjacent structures 
and inversely related to prognosis (Merendino et al., 1952; Takagi and Karasawa, 1982).  
 
1.1.6 Detection and Diagnosis 
1.1.6.1 Clinical symptoms 
Most oesophageal cancers do not cause symptoms until they have reached an advanced stage, 
resulting in late diagnosis of the disease and a poor prognosis. The principle symptom of 
oesophageal cancer is difficulty swallowing or dysphagia accompanied by weight loss 
(Enzinger and Mayer, 2003). Long-standing gastroesophageal reflux disease is often a 
nonspecific sign of OSCC (Nebel et al., 1976). Dyspnoea, cough, hoarseness and pain occur 
less frequently but may reflect the presence of extensive unresectable disease (Freitag et al., 
1996). Lymphadenopathy, particularly in the left supraclavicular fossa (Virchows node), 
hepatomegaly and pleural effusion are all common signs of metastatic disease (Enzinger and 
Mayer, 2003). 
 
1.1.6.2 Diagnostic investigations 
Initial investigation comprises either an oesophagoscopy and incisional biopsy for 
confirmation of tumour and tumour subtype, or a barium swallow aimed at detecting either 
strictures or ulcerations of the oesophagus, or both (Enzinger and Mayer, 2003). Further pre-
treatment evaluation is generally performed with a computer tomography (CT) scan, magnetic 
resonance tomography (MRT), or endoscopic ultrasound (EUS) to determine tumour extent.  
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The presence of distant metastases in the abdomen is determined by a CT scan or ultrasound 
or both (Stein et al., 2001). Positron-emission tomography (PET) has also been used to detect 
metastatic disease as it is less invasive than thoracoscopic or laparoscopic techniques 
(Enzinger and Mayer, 2003). Mass screening programs in high incidence areas, such as China, 
have helped in the early detection of OSCC. Early detection methods include abrasive brush 
cytology, occult blood bead detection and endoscopy in conjunction with Lugol iodine 
solution (Chen et al., 1999).  
 
1.1.7 Staging  
The union internationale contre le cancer (UICC) tumour-node-metastases (TNM) staging 
system is used to determine the extent of disease progression (Hermanek and Sobin, 1987). 
This system takes into account the characteristics of the primary tumour, regional node 
metastases and distant metastases (Table 1.1). Staging of the tumour is the key to diagnosis, 












Table 1.1 The TNM classification system for the staging of oesophageal cancer  
 
  
Primary Tumour (T) TX Primary tumour cannot be assessed 
 T0          No evidence of primary tumour 
 Tis Carcinoma in situ 
  T1 Tumour invasion of lamina propria or submucosa 
 T2 Tumour invasion of muscularis propria 
  T3 Tumour invasion of adventia 
  T4 Tumour invasion of adjacent structures 
   
Regional Lymph Node (N) NX Regional lymph nodes cannot be assessed 
 N0 No regional node metastasis 
 N1 Regional lymph node metastasis 
  
Distant Metastasis (M) MX Presence of distant metastasis cannot be assessed 
 M0 No distant metastasis 
 M1 Distant metastasis 
Stage Grouping  
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage IIA T2 N0 M0 
 T3 N0 M0 
Stage IIB T1 N1 M0 
 T2 N1 M0 
Stage III T3 N1 M0 
 T4 Any N M0 








1.1.8 Treatment and prognosis 
Oesophageal carcinoma has one of the lowest rates of cure with overall 5-year survival rates 
of 10% (Holmes and Vaughan, 2006). Prognosis depends on the depth of tumour penetration 
of the oesophagus and the extent of lymph node metastases (Ellis et al., 1993). In the early 
stage disease (Stage I-II) surgical treatment with curative intent is offered to patients who are 
in good medical condition (Enzinger and Mayer, 2003). In patients with intra-epithelial 
cancer, the risk of lymph node metastasis is low and resection of the tumour by means of a 
complete or partial oesophagectomy carries a good prognosis (Sugimachi et al., 1993). The 
incidence of perioperative complications such as infections, anastomosis leakage, and 
pulmonary complications is however high (26-41%) (Enzinger and Mayer, 2003).  In tumours 
that have invaded the submucosa, the incidence of lymph node metastasis is as high as 60%, 
indicating a poor prognosis (Kato et al., 1993).  
 
At the time of diagnosis of oesophageal cancer, more than 50 percent of patients have either 
unresectable tumours or radiographically visible metastases, and an expected survival time of 
less than one year. Management methods for advanced disease include palliative resection, 
radiotherapy, brachytherapy, chemotherapeutic drugs, and dilatation techniques for 
maintaining the oesophageal lumen (Enzinger and Mayer, 2003). In an attempt to improve 
survival rates, combined treatment modalities including radiotherapy and chemotherapy 
together with surgery have been investigated in several randomised clinical trials. Although 
these studies of new combination chemotherapeutics have reported higher response rates, the 





Knowledge of the molecular basis of cancer aetiology and progression may lead to a clearer 
understanding of oesophageal cancer. The transformation of a cell from a normal state to a 
malignant one is known as carcinogenesis. This process can be divided into three different 
phases: initiation, promotion and progression. Initiation involves an irreversible genetic 
change, usually a mutation in a single gene. Promotion is the increased proliferation of 
initiated cells while progression is the subsequent accumulation of a further sequential series 
of genetic mutations or alterations that produce the malignant phenotype (Martinez et al., 
2003). Each of these genetic alterations is thought to provide the developing tumour cell with 
significant growth advantages that allow tumour cells to outnumber normal neighbouring cells 
(Nowell, 1976).   
 
Three classes of normal regulatory genes are the principle targets of genetic damage. These 
are growth promoting proto-oncogenes, growth-inhibiting tumour suppressor genes (anti-
oncogenes), and genes that regulate programmed cell death or apoptosis (Martinez et al., 
2003). Proto-oncogenes that have undergone mutational damage are known as oncogenes. 
These genes are capable of transforming cells despite the presence of a normal chromosomal 
counterpart, that is, they are dominant in nature. In contrast, tumour suppressor genes are 
recessive in nature as both normal alleles must be affected for transformation to occur 
(Martinez et al., 2003).  The DNA repair genes are another class of genes that are important in 
carcinogenesis. These genes affect cell survival and proliferation as they have the capability to 
repair non-lethal damage to DNA. Loss of function of DNA repair genes as a result of 
mutational changes, leads to widespread mutations in the genome and neoplastic 
transformation. 
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The complexity of the wide variety of different cancer types, together with the broad and 
diverse range of cancer associated genes, confounds the exact cause underlying the process of 
carcinogenesis. It has been suggested that the majority of cancer cell genotypes result in six 
essential alterations in cell physiology that lead to malignant growth, namely, 
1. Self sufficiency in growth signals 
2. Insensitivity to growth inhibitory signals 
3. Evasion of apoptosis 
4. Limitless replicative potential 
5. Sustained angiogenesis 
6. Tissue invasion and metastasis 
Mutations or altered functions in the genes that regulate these cellular traits are seen in most 
cancers, although the precise genetic events that give rise to these properties may differ 
between cancers (Hanahan and Weinberg, 2000). 
 
1.2.1 Mutations 
The types of mutations or genetic alterations that can occur in carcinogenesis include point 
mutations, frame-shift mutations, chromosomal imbalance or instability, chromosomal 
translocations or rearrangements and epigenetic modifications to DNA (Bertram, 2001). 
Spontaneous mutations are a frequent event due to the inherent instability of DNA and arise 
either as a consequence of errors in replication or direct damage to DNA. 
 
Most mutations are overcome by DNA repair genes (Bertram, 2001). The protein products of 
these genes survey the genome for damage and then restore the damaged sequence, protecting 
against immediate and long term effects of excessive mutational rates.  
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Defects in these repair processes result in an increase in the rate of mutation and consequently 
the rate of neoplastic progression. Both chemical and physical agents that cause damage to 
DNA are known as environmental carcinogens. These include chemical carcinogens such as 
polycyclic aromatic hydrocarbons, dimethylnitrosamine, N-nitrosamines, and 
chemotherapeutic agents and physical agents such as ionising and ultraviolet radiation. 
Chemical damage to DNA alone is not a mutagenic event. It is DNA replication and 
consequent cell division that converts chemical damage to a reproducible change in DNA.  
Abnormal cellular proliferation is a major factor in the development of tumours despite 
numerous checkpoints in normal cellular processes designed to restrict uncontrolled growth. 
Malignant cells must acquire several mutations in key genes to maintain autonomous 
replication and invasion (Bertram, 2001). 
 
1.2.2 Epigenetic changes 
The normal functioning of genes can also be disrupted through genetic alterations which 
modify the expression of the gene (Martinez et al., 2003). These epigenetic mechanisms, such 
as DNA methylation, can result in gene silencing, early loss of cell cycle control, altered 
regulation of gene transcription factors and multiple types of genetic instability all of which 
are characteristic of neoplasia. Hypermethylated genes implicated in human cancers include 
tumour suppressor genes that cause familial forms of cancer when mutated in the germline e.g 
adenomatous polyposis coli gene (APC), breast cancer gene (BRCA-1) and epithelial cadherin 






Most normal human cells have a turnover capacity of 50 to 100 generations after which 
replicative senescence occurs. This is the result of progressive shortening of telomeres at the 
ends of chromosomes which leads to chromosome abnormalities and cell death. In contrast, 
most tumour cells are capable of unlimited replication by avoiding cellular senescence. 
Massive proliferation is required for the progression of carcinogenesis and 85-95% of cancers, 
including oesophageal tumours, have been shown to reactivate telomerase in order to retain 
telomere length (Bertram, 2001).  
 
1.2.4 Cell cycle 
The cell cycle directs cellular proliferation. It consists of a series of checks and balances that 
monitor nutritional status, cell size, the presence or absence of growth factors and the integrity 
of the genome. Cell division consists of four stages namely, gap phase 1 (G1), synthesis (S), 
gap phase 2 (G2) and mitosis (M). Resting cells are said to be in the gap phase 0 (G0). DNA is 
replicated during the S phase and chromosome segregation takes place during the M phase. 
Once cells enter the replicative stages they are committed to complete cell division. Exit from 
the G1 stage and entry into the S stage is stringently controlled in normal cells but often 
misregulated in tumour cells that exhibit uncontrolled proliferation. Amongst key genes 
orchestrating the cell cycle are cyclins, cyclin-dependent kinases (CDKs) and cyclin-dependent 
kinase inhibitors (CDKIs). Mutations that dysregulate the activity of these genes appear to 






The ability of tumour cell populations to increase in number is determined by both the rate of 
cell proliferation and the rate of cell attrition. Programmed cell death, or apoptosis, is 
genetically controlled and essential for processes such as embryogenesis and maintenance of 
cellular homeostatic balance. The apoptotic pathway is regulated by sensors and effectors.  
Sensors monitor the intracellular and extracellular environment for conditions that influence 
the fate of the cell. Signals by sensors evoke effectors that are either survival or death factors 
(Hanahan and Weinberg, 2000). Factors such as DNA damage, signaling imbalance provoked 
by oncogene action, survival factor insufficiency or hypoxia cause sensors to evoke the death 
pathway (Evan and Littlewood, 1998). Acquired resistance towards apoptosis or the ability to 
evade apoptosis are characteristics of many types of cancer. Enabling strategies include 
overexpression of the Bcl-2 oncogene, inhibition or mutations of the Fas receptor gene and 
mutations of the p53 gene (Hanahan and Weinberg, 2000).  
 
1.2.6 Oncogenes 
As mentioned previously, oncogenes are normal host cellular regulatory genes (proto-
oncogenes) that have become dysregulated as a consequence of mutations or genetic 
alterations. They contribute to the carcinogenic process by the acceleration of cell proliferation 
or the reduction of sensitivity to cell death. To achieve this, oncogenes produce aberrantly 
functioning proteins which are able to activate growth signaling circuits even in the absence of 
normal growth promoting signals. This drives cellular proliferation beyond the levels of 
normal cellular growth (Weinberg, 1994).  
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The different types of oncogenes include growth factors, growth factor receptors, cytoplasmic 
tyrosine kinases, serine-threonine tyrosine kinases, nuclear proteins, cytoplasmic proteins and 
membrane-associated guanine nucleotide-binding proteins that influence cell survival 
(Martinez et al., 2003).  For example, human epidermal growth factor receptors-1 and -2 
(HER1, HER2) are oncogenes that are activated by amplification mutations and are frequently 
associated with many different types of carcinoma, including OSCC as will be discussed in 
section 1.3.1.  
 
1.2.7 Tumour suppressor genes 
Cellular proliferation can be inhibited by the action of tumour suppressor genes. Direct 
inhibition of cell growth by these gene products is rate limiting (Martinez et al., 2003). Both 
normal alleles of tumour suppressor genes need to be functionally affected for tumours to 
develop. Mutations that inactivate only one allele are frequently inherited through the 
germline, and in combination with a somatic mutation on the other allele, can cause cancer 
predisposition syndromes. For example, multiple mutations in the p53 tumour suppressor gene 
result in the Li-Fraumani syndrome (Bertram, 2001).  The retinoblastoma (Rb) and p53 genes 
are well documented examples of tumour suppressor genes. The Rb gene regulates the entry of 
cells into the cell cycle. Loss of Rb function causes the deregulation of the cell cycle resulting 
in uncontrolled cell proliferation and ultimately tumour formation. Homozygous mutations in 
the Rb gene are frequently found in breast, lung and bladder cancers (Kumar et al., 2003). In 
oesophageal cancer, alterations in the Rb gene have been reported in some tumours (Jiang et 
al., 1993; Roncalli et al., 1998). 
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The p53 tumour suppressor gene directs the cell towards an appropriate response, cell cycle 
arrest or apoptosis, in order to maintain genomic stability. When DNA damage occurs, the p53 
protein detects and contributes to DNA repair by causing cell cycle arrest and inducing DNA 
repair genes. Cells with irreparable DNA are bound for apoptosis directed by the p53 gene. 
When there is homozygous loss of p53 function, DNA damage remains unrepaired, leading to 
malignant transformation (Bertram, 2001). Over 70% of human cancers have defects in the 
function of the p53 gene (Levine, 1997). The prevalence of p53 aberrations in oesophageal 
cancer ranges from 10 to 85% (Lam et al., 1995). Immunohistochemical studies carried out in 
South Africa indicated that p53 is overexpressed in approximately 40-50% of oesophageal 
cancer tumours (Chetty and Simelane, 1999; van Heerden et al., 1998).  
 
1.3 Oesophageal cancer-related genes 
There are numerous genes implicated in carcinogenesis of the oesophagus. These include 
oncogenes, tumour suppressor genes, genes for apoptosis, growth factors, growth factor 
receptors, cell cycle regulators and signal transducers (Lam et al., 1995; Lam, 2000).  The 
present study focuses on the expression of four genes that are implicated in oesophageal 
carcinogenesis. These include the genes for human epidermal growth factor receptors-1 and -
2 (HER1 and HER2), vascular endothelial growth factor (VEGF) and matrix 







1.3.1 Human epidermal growth factor receptor-1 and -2  
Human epidermal growth factor receptor-1 (HER1), also known as epidermal growth factor 
receptor (EGFR) or ErbB-1 and human epidermal growth factor receptor-2 (HER2) also 
known as ErbB-2 or Neu, belong to the HER family of receptor tyrosine kinases (RTK) 
(Yarden, 2001). Ancestral forms of the HER molecule that exhibit tyrosine kinase activity are 
found in invertebrates and in simple life forms such as the worm Caenorhabditis elegans and  
the fruit fly Drosophila melanogaster (Yarden, 2001). This family of receptor tyrosine kinases 
regulates a variety of signal transduction cascades that modulate growth, differentiation, cell 
motility and survival. The aberrant activity of members of this receptor family is a vital feature 
in the development and growth of tumour cells (Yarden, 2001).  
 
1.3.1.1 Structure of the HER Family 
The HER family consists of four closely related growth factor receptors: HER1, HER2, HER3, 
and HER4 (Yarden, 2001). Each of these receptors has an extracellular ligand-binding 
domain, a single hydrophobic transmembrane domain and a cytoplasmic tyrosine kinase 
containing domain (Olayioye et al., 2000). The intracellular tyrosine kinase domain of the 
HER receptors are highly conserved, with the exception of HER3 which contains substitutions 
of vital amino acids and hence lacks kinase activity (Guy et al., 1994). The extracellular 
domains of the four receptors are less conserved implying that they have different specificities 
in ligand binding (Olayioye et al., 2000). The HER2 receptor is encoded by the HER2 gene, a 
proto-oncogene mapped to chromosome 17q21. It is a 1255 amino acid, 185kD 
transmembrane glycoprotein (Coussens et al., 1985). The HER1 gene is located on 
chromosome 7p12 and encodes the HER1 receptor which is a 170kD cell surface glycoprotein 
consisting of 1186 amino acids (Arteaga, 2001). 
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1.3.1.2 Ligands of HER receptors 
Human epidermal growth factor receptors are activated by binding to the ligands within 
epidermal growth factor (EGF) family. These ligands consist of a characteristic EGF-like 
domain that confers binding specificity and extra structural motifs such as immunoglobulin-
like domains, heparin-binding sites and glycosylation sites (Normanno et al., 2005). Ligand 
binding to HERs results in the formation of receptor homo- or hetero-dimerisation, tyrosine 
kinase activation and initiation of signaling cascades. Receptor dimerisation is essential 
because it allows a signaling network to transmit a diverse array of biological messages 
(Olayioye et al, 2000). 
 
The HER1 receptor binds to several ligands. These include EGF, transforming growth factor α 
(TGF-α), amphiregulin (AR), betacellulin (BTC), heparin-binding growth factor (HB-EGF) 
and epiregulin (EPR) (Carraway et al., 1997; Chang et al., 1997; Zhang et al., 1997). None of 
the EGF family of peptides binds HER2 (Normanno et al., 2005). HER2 has a greater capacity 
for heterodimerisation due to its structure and conformation and is the preferred dimerisation 
partner for all other HER receptors (Graus-Porta et al., 1997; Tzahar et al., 1996). The HER2 
containing heterodimers are the most effective complexes, increasing biological responses 
such as cellular proliferation, migration and invasion. The combination of HER2/HER3 is the 







1.3.1.3 Biological function of the HER family 
The HER family of growth factor receptors forms part of an intricate signal transduction 
network which is central to important cellular processes such as cell proliferation, migration, 
survival and adhesion. The type and duration of signal transduction pathways activated by 
HERs depend on the identity of the ligand, constitution of the receptor complex, and structural 
determinants of the ligands. For example, the ras/raf/MEK/mitogen-activated protein kinase 
(MAPK) which drives cellular proliferation, and the phosphoatidylinositol 3-kinase /Akt 
pathway which regulates cellular survival and anti-apoptotic signals, are both activated by all 
HER ligands (Citri et al., 2003). The HERs also interact with integrins which mediate cell-cell 
adhesion, cell-matrix association, intracellular signaling and cell migration, as well as 
activating many transcription factors, such as c-fos and c-myc (Olayioye et al., 2000; Sieg et 
al., 2000). All the intracellular signaling pathways activated through HERs occur in the 
nucleus where cell cycle regulators and transcription factors control the biological outcome of 
HER activation (Normanno et al., 2005). Several negative regulatory pathways exist which 
attenuate signaling through HERs in order to maintain suitable signal regulation for normal 
development. In humans, the main signal attenuation is through the downregulation of surface 
receptor levels by a procedure known as “ligand-induced endocytosis” (Carpenter, 2000). 
During signal termination, ligand-receptor complexes are internalised through the plasma 







1.3.1.4 Role of HERs in carcinogenesis 
The HER system is associated with many human cancers. The dysregulation of signaling 
pathways induced through these receptors stimulates characteristic processes typical of cancer 
cells such as, proliferation, migration, angiogenesis, stromal invasion and resistance to 
apoptosis (Klapper et al., 2000). Hyperactivation of the HER network occurs in an autocrine 
or paracrine manner. Tumour cells overproduce growth factors and their receptors by using 
autocrine secretory loops or depend on adjacent stromal cells to provide HER ligands 
(Salomon et al., 1995). Evidence suggests that overexpression of both HER1 and HER2 in a 
ligand-dependent manner, is a contributing factor in carcinogenesis (Frederick et al., 2000). 
Aberrant growth of cells can also occur through constitutive receptor activation, that is, the 
activation of a growth factor receptor in the absence of a ligand (Lonardo et al., 1990). 
EGFRvIII is a common HER1 mutant that stimulates cellular proliferation in the absence of 
ligands (Ekstrand et al., 1994). It is frequently found in malignant gliomas, breast carcinomas, 
non-small-cell lung carcinomas and ovarian carcinomas (Garcia de Palazzo et al., 1993; 
Moscatello et al., 1995; Moscatello et al., 1996; Wikstrand et al., 1995).  
 
Gene amplification, overexpression, re-arrangements or mutations of HER1 and HER2 are 
found in many human malignancies. It has been reported that cancers with high expression of 
either HER1 or HER2 have a better prognosis than cancers that have a high expression of both 
receptors (Iwase et al., 1997; Xia et al, 1999). In a study by Brabender and colleagues (2001), 
co-expression of HER1 and HER2 was a better predictor for treatment failure and poor 
survival than HER1 expression alone in patients with non-small cell lung carcinoma (NSCLC) 
(Brabender et al., 2001).  
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Several studies have investigated the use of HER2 expression to predict clinical behaviour in 
breast cancer patients. It was reported that HER2 gene amplification and/or protein 
overexpression in node positive breast cancer patients was predictive of a poor outcome, 
independently of other prognostic indicators. In contrast, HER2 expression in node negative 
patients was less informative (Gullick, 1990; Ravdin and Chamness, 1995). Due to the 
frequent overexpression and high signaling potential, HER1 and HER2 are promising 
therapeutic targets in human cancer. One of the most successful examples is the development 
of the monoclonal antibody, Herceptin (Trastuzumab), which recognises the extracellular 
domain of HER2 and was one of the first target-selective drugs raised against the oncogenic 
cell-surface receptor (Fendly et al., 1990). Clinical studies have shown Herceptin to be well 
tolerated in women with metastatic breast cancer overexpressing HER2 and to produce 
durable objective responses (Baselga et al., 1996; Cobleigh et al., 1999). 
 
Overexpression of HER1, ranging from 2 to 100 fold, is a frequent genetic alteration in 
premalignant oesophageal dysplastic lesions and in the early stages of OSCC, and has been 
correlated with a poor prognosis (Hirai et al., 1998; Iihara et al., 1993; Inada et al., 1999; Lin 
et al., 1984). The overexpression of HER1 has also been associated with depth of invasion of 
the tumour, suggesting that it may play a role in the process of tumour infiltration (Hanawa et 
al., 2006). In a study by Andl and colleagues (2003), it was demonstrated that HER1 
overexpression in OSCC was not sufficient to induce cancer but led to increased cell 
proliferation, migration and aggregation. Amplification of the HER1 gene was also reported in 
this study and suggested to occur in the early stages of carcinogenesis (Andl et al., 2003).  
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With respect to HER2, overexpression has been reported in several studies on OSCC and has 
been associated with gene amplification and poor survival (Chiang et al., 1999; Dreilich et al., 
2006; Kleef et al., 2002; Lam et al., 1998; Nakamura et al., 1994).  
 
1.3.2 Vascular endothelial growth factor 
Vascular endothelial growth factor (VEGF) is the most common growth factor observed at 
almost all sites of angiogenesis. In addition, levels of VEGF have been correlated with blood 
vessel growth (Robinson and Stringer, 2001). Angiogenesis is the process by which new blood 
vessels develop from pre-existing blood vessels and it impacts significantly on many disease 
states including cancer, ischaemic cardiovascular disease, wound healing and inflammation 
(Dvorak, 2002).  
 
1.3.2.1 Identification of VEGF 
VEGF was first identified as a vascular permeability-inducing factor secreted by tumour cells 
and was called vascular permeability factor (VPF) (Senger et al., 1983). It was thought to be a 
mediator of the high permeability of tumour blood vessels. Subsequently, a diffusible 
endothelial cell-specific mitogen known as vascular endothelial growth factor (VEGF) was 
discovered in bovine pituitary folliculo-stellate cells (Ferrara and Henzel, 1989; Plouët et al, 
1989). Amino acid sequencing showed that this protein was distinct from any other known 
endothelial cell mitogen while cDNA cloning of VPF and VEGF demonstrated that VEGF and 





1.3.2.2 The VEGF gene and protein structure 
The VEGF supergene family of growth factors include VEGFs A, B, C, D, E and placenta 
growth factor (PGF) (Dvorak, 2005). All have a structural homology to platelet-derived 
growth factor (PDGF) (Dvorak, 2002). The VEGF protein is a highly conserved disulphide-
bonded homodimeric glycoprotein of 45 kD. The two chains that constitute VEGF form an 
anti-parallel homodimer covalently linked by two disulphide bridges (Muller et al., 1997). 
Each monomer is characterised by an intrachain disulphide bonded knot motif at one end of a 
four stranded β sheet. The principle element within the monomer is the cysteine knot motif 
(Muller et al., 1997). The VEGF-A protein is encoded by a single gene that is located on 
chromosome 6p21.3 (Vincenti et al., 1996). The coding region spans 14kb and contains eight 
exons. Alternative splicing of a single mRNA molecule can yield several different isoforms of 
VEGF-A that vary in length i.e. 121, 145, 165, 189 and 206 amino acids, and differ by the 
presence or absence of sequences located in exons 6 and 7 (Robinson and Stringer, 2001). 
Exon 8 is common to all isoforms (Tischer et al., 1991). The VEGF 165 is reported to be the 
predominant isoform. The information encoded by this alternative splicing determines whether 
VEGF is freely soluble or bound to the extracellular matrix or plasma membrane proteins, or 
has properties of both.  
 
1.3.2.3 VEGF receptors 
VEGF-A binds two related RTKs, namely VEGFR-1 (also called fms-like tyrosine kinase [Flt-
1]) and VEGFR-2 (also referred to as kinase insert domain, [KDR] and murine homologue 
[Flk-1]). These two receptors share 44% homology and have a typical structure consisting of 
seven immunoglobulin-like domains, a single transmembrane domain, and a consensus 
tyrosine kinase domain interrupted by a kinase insert domain (Shibuya et al., 1990).  
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The VEGFR-1 is a high affinity receptor for VEGF-A, but also has the ability to bind to 
VEGF-B and PGF. Studies have reported that this receptor is essential for physiological and 
developmental angiogenesis, and is a potent positive regulator of angiogenesis during 
tumourigenesis (Peters et al., 1993; Fong et al., 1995; Hiratsuka et al., 2001). The VEGFR-2 is 
a high affinity receptor for VEGF-A as well as VEGF-C and D and also plays an important 
role in vasculogenesis (Robinson and Stringer, 2001). The VEGFR-3 (also called fms-like 
tyrosine kinase 4 [Flt-4]) binds to VEGF-C and VEGF-D but not VEGF-A, and has been 
mainly associated with lymphangiogenesis (Kaipainen et al., 1995).  
 
1.3.2.4 Biological activities of VEGF-A 
The VEGF-A together with the fibroblast growth factor (FGF) and activators of integrins, is 
one of the main stimulators of angiogenesis (Folkman, 2003). As mentioned previously, 
angiogenesis is essential for a wide range of fundamental physiological processes such as 
embryogenesis, somatic growth, wound healing, tissue and organ regeneration. Aberrant and 
uncontrolled proliferation of blood vessels is an important component of diseases such as 
cancer, rheumatoid arthritis, psoriasis, retrolental fibroplasias and retinopathies (Ferrara et al., 
1992). The angiogenic cascade is a complex process that is mediated by the endothelial cells 
that line blood vessels. The VEGF-A mediates angiogenesis and other functions through the 
stimulation of specific receptors on endothelial cells to activate the expression of endothelial 
cell genes. This leads to the production of proteins such as procoagulant tissue factor, proteins 
associated with fibrinolytic pathway, matrix metalloproteases, nitric oxide synthase, integrins 
and various mitogens (Dvorak, 2002).   
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Activation of the VEGF-VEGF-receptor axis triggers many signaling networks that result in 
endothelial cell survival, mitogenesis, migration and differentiation, vascular permeability and 
mobilization of endothelial progenitor cells (Hicklin and Ellis, 2005). Endothelial cell 
migration and invasion following the degradation of the basement cell membrane is an 
important step in the initiation of angiogenesis (Rafii and Lyden, 2003).   
  
1.3.2.5 VEGF-A and tumour angiogenesis 
Tumour angiogenesis is the vascular proliferation of a network of blood vessels that penetrates 
into cancerous growths, supplying nutrients and oxygen and removing waste products. It 
allows the tumour to maintain its growth advantage and also facilitates metastatic spread by 
establishing connections to the existing vasculature (Folkman, 1971). The vessels formed by 
tumour angiogenesis are highly abnormal, non-uniformly distributed, irregularly branched, 
with arterio-venous shunts, hyperpermeable to plasma and plasma proteins and do not 
conform to a clear hierarchical pattern (Dvorak, 2003). The angiogenic cascade leading to 
tumour vascularisation is divided into the prevascular phase, also known as the “angiogenic 
switch” and the vascular phase (Pepper et al., 1996). When tumour cells undergo 
transformation to the angiogenic phenotype, phenotypic changes on endothelial cells as well 
as other cell types are induced. At this point avascular tumours can acquire their own blood 
supply and grow rapidly (Norrby, 1997). Tumours lacking adequate vasculature become 
necrotic or apoptotic, whereas tumours that have undergone neovascularisation enter a phase 
of exponential growth and have increased metastatic potential (Brem et al., 1976; Holmgren et 
al., 1995).  
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The VEGF-A is a key regulator of normal and pathological angiogenesis. Its expression in 
active cells is controlled by a variety of external factors. Some of these factors are briefly 
discussed below and include hypoxia, growth factors and cytokines, oncogenes and tumour 
suppressor genes.  
 
As tumours expand, the cells within the expanding mass are deprived of oxygen as distance 
from the nearest blood vessels increases, resulting in hypoxic regions within tumours. Cells in 
hypoxic regions respond by stimulating VEGF-A production which in turn activates 
angiogenesis (Ferrara and Davis-Smyth, 1997). Hypoxic transcriptional regulation of VEGF-A 
is mediated by hypoxia-inducible factor 1 (HIF-1) (Dvorak, 2002).  
 
Many studies have shown that certain growth factors and cytokines can also induce 
angiogenesis. The HER1 and HER2 genes have been shown to be involved in VEGF-A 
regulation and angiogenesis in tumours such as colon carcinoma, renal cell carcinoma and 
breast cancer (Ciardiello et al., 2000; Kedar et al., 2002; Yang et al., 2002). Prostaglandins 
have also been implicated in tumour angiogenesis by upregulation of VEGF-A expression 
(Gately, 2000). In addition, prostaglandin-endoperoxide synthase-2/ cyclo-oxygenase-2 
(COX-2) overexpression has been shown to be associated with tumour progression and 
elevated angiogenesis in several solid malignancies including breast, colon and pancreatic 
cancers (Aoki et al., 2002; Costa et al., 2002; Tsujii et al., 1998). Platelet derived growth 





Many oncogenes and tumour suppressor genes have been associated with the modulation of 
angiogenesis in solid tumours due to the ability to induce pro-angiogenic growth factors such 
as VEGF.  The induction of VEGF by a mutant Ras oncogene has been reported in several 
types of cancer (Rak and Kerbel, 2001). The p53 tumour suppressor gene impacts on the 
regulation of VEGF-A in malignant tumours by suppressing VEGF-A transcription.  
 
1.3.2.6 VEGF-A in cancer 
In many different types of carcinomas, including oesophageal, overexpression of VEGF-A has 
been reported to correlate with poor prognosis (Adams et al, 2000; Borre et al., 2000; Cascinu 
et al., 2000; Kaya et al., 2000; Loncaster et al., 2000; Mineta et al., 2000; Shen et al., 2000; 
Shih et al., 2000; Slaton et al., 2001; Tabone et al., 2001; Yudoh et al., 2001). In addition, 
VEGF-A expression correlated with one or more of the following prognostic measures: 
tumour size, metastasis, and overall survival, thereby providing evidence that the amount of 
VEGF-A expressed by tumours affects clinical outcome. The identification of VEGF-A as a 
central regulator of angiogenesis has led to efforts to exploit its therapeutic potential. Anti-
angiogenesis treatment modalities currently in preclinical and clinical development focus on 
the inhibition of the VEGF-A pathway, using different approaches (Ellis et al., 2001). These 
include synthetic neutralising antibodies to VEGF-A or VEGF receptors, tyrosine kinase 
inhibitors to VEGF receptors, and soluble VEGR receptors/ VEGF receptor hybrids (Ellis et 






1.3.3 Matrix metalloproteinase 2 (MMP 2)/ gelatinase A 
Matrix metalloproteinases are involved in a variety of normal biological processes such as 
embryonic development, blastocyst implantation, organ morphogenesis, nerve growth, 
ovulation, cervical dilatation, bone remodeling, wound healing and angiogenesis. They are 
also implicated in pathological processes, such as arthritis, cancer, cardiovascular disease and 
neurological disease. The main function of MMPs is the removal of the extracellular matrix 
(ECM) during tissue resorption and the alteration of biological functions of extracellular 
matrix macromolecules by specific proteolysis (Nagase and Woessner, 1999).  
 
1.3.3.1 Identification of matrix metalloproteinases 
Matrix metalloproteinases belong to a family of zinc dependent endopeptidases of the 
superfamily metzincins. In humans, more than 21 MMPs have been identified. They all have 
the characteristic ability to cleave ECM proteins (Birkedal-Hansen et al., 1993). The MMPs 
were initially divided into collagenases, gelatinases, stromelysins and matrilysins on the basis 
of their specificity for ECM components. However, due to the identification of increasing 
numbers of substrates, a sequential numbering system was adopted. The MMPs are now 
grouped according to their structure (Stamenkovic, 2000). 
 
1.3.3.2 Structure of matrix metalloproteinase 2 
Matrix metalloproteinase 2 belongs to the group of gelatinases. These proteins preferentially 
degrade denatured collagens and gelatins. Structurally, MMP2 is a 72 kDa type IV collagenase 
and is coded for by the gene located on chromosome 16q13 (Visse and Nagasse, 2003).  
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All MMPs are produced as zymogens containing a secretory signal sequence and a propeptide 
whose proteolytic cleavage is needed for MMP activation (Visse and Nagasse, 2003). In 
general, MMPs contain a signal peptide, a propeptide, a catalytic domain with the highly 
conserved zinc binding site and a hemopexin-like domain linked to the catalytic domain by a 
hinge region as seen below in Figure 1.4 (Egeblad and Werb, 2002).  
 
 
Figure 1.4. Protein structure of MMP2, a gelatin binding matrix metalloproteinase, containing a 
prepeptide (Pre) with an amino-terminal signal sequence, a propeptide (Pro) with a zinc interacting 
thiol group (SH), and a catalytic domain with a zinc binding site and inserts of fibronectin (Fi) hinged 
(H) to hemopexin domains that are linked by a disulphide bond (S-S) (Egeblad and Werb, 2002) 
 
The propeptide domain has a conserved amino acid sequence. A Cysteine within this region, 
known as the “cysteine switch”, ligates the catalytic zinc binding motif to maintain the latency 
of pro-MMPs (Becker et al., 1995; Bode et al., 1993). Additionally, MMP2 contains 
fibronectin type II inserts within the catalytic domain (Nagase and Woessner, 1999).  
 
1.3.3.3 MMP2 activation 
Matrix metalloproteinases are expressed in tissues at various stages of development. They are 
rapidly induced by external stimuli such as growth factors and cytokines, as well as by 
changes in cell-cell and cell-ECM interactions. The activity of MMPs is controlled at three 
levels: transcription, proteolytic activation of the zymogen and inhibition of the active enzyme 
(Stamenkovic, 2003).  
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Most MMPs, including MMP2, are secreted in latent precursor form and are activated in the 
extracellular space. The propeptide latency is established by the cysteine switch (Stamenkovic, 
2003). When this switch is disrupted, the propeptide is removed resulting in the activation of 
the MMPs. Secreted pro-peptides are activated in vitro by proteinases and by non-proteolytic 
agents such as SH reactive agents, mercurial compounds, reactive oxygen and denaturants 
(Nagase and Woessner 1999).  
 
In vitro, MMPs are able to mutually activate each other as well as autoactivate, for example, 
MMP1 and MMP12 can activate latent MMP2 (Stamenkovic, 2000). Matrix metalloproteinase 
2 is activated mainly by cell surface activation as pro-MMP2s are not easily activated by 
proteinases. Pro-MMP-2 forms a tight complex with tissue inhibitors of MMP2 (TIMP-2) in 
its process of activation (Strongin et al., 1995). Tissue inhibitors of MMPs (TIMPs) are major 
endogenous regulators of MMP activity. Four types are known, TIMP-1 to TIMP-4, as well as 
the serum proteinase inhibitor, α-2 macroglobulin (Baker et al., 2002). Tissue inhibitors bind 
to conserved regions of active MMPs and inhibit their proteolytic activity.  
 
1.3.3.4 Biological function of MMPs 
As mentioned previously, matrix metalloproteinases, including MMP2, are responsible for 
proteolytic degradation of the extracellular matrix (ECM) and the basement membrane during 
tissue remodelling. The ECM and basement membrane play a crucial part in both tissue 
architecture and homeostasis, the exact nature of which depends on the tissue type. Thus each 
tissue has different types of ECM. The basement membrane is a specialised form of ECM. It is 
a thin flexible mat that separates epithelial cells from the underlying stroma.  
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Matrix metalloproteinases are important in embryonic development as ECM remodelling is a 
key component of tissue growth and morphogenesis (Visse and Nagase, 2003). Matrix 
metalloproteinases also influence many developmental and physiological cellular functions by 
degradation and alteration of the ECM micro-environment leading to cell migration, 
proliferation, apoptosis or morphogenesis. Metalloproteinases modulate the activity of growth 
factors, growth factor receptors and proteases by cleavage from the ECM or by cleavage of 
enzymes or their inhibitors (Vu and Werb, 2000). 
 
1.3.3.5 Matrix metalloproteinase 2 and tumour progression 
Tumour cell invasion and metastasis is a multi step process involving the proteolytic 
degradation of basement membranes, altered cell adhesion and physical movement of tumour 
cells. Matrix metalloproteinases are believed to create an environment that supports the 
initiation and growth of primary tumours, enhances tumour angiogenesis and 
neovascularisation, and enables the disruption of local tissue architecture and penetration of 
connective tissue barriers. This facilitates dissemination of cancer cells and metastatic spread 
(Ohtani, 1998).  
 
The process of tumour cell invasion and metastasis involves extensive remodeling of the ECM 
and basement membranes. For the change from in situ to invasive malignancy, tumour cells 
must penetrate their delimiting basement membranes and move through surrounding stroma. A 
metastatically competent cell must have access to the vascular or lymphatic systems and 
extravasate at a distant site to establish new proliferating colonies (Egeblad and Werb, 2002). 
Cleavage of ECM components by MMPs generates proteolytic fragments that enhance tumour 
cell migration.  
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Cleavage of laminin-5 and -14 by MMP2, results in laminin fragments that trigger migration 
signals in cells (Gianneli et al, 1997; Koshikawa et al., 2000). Several studies have provided 
evidence for involvement of MMPs in the metastatic process. Overexpression of MMP2 
protein has been shown to promote cellular invasion in tumour cell lines and animal models, 
strongly implicating the MMP2 gene in metastasis (Deryugina et al., 1997; Itoh et al., 1998). 
In vitro and in vivo studies have also implicated a role for MMPs in angiogenesis. The MMP2 
gene has been demonstrated to be necessary for the switch to an angiogenic phenotype while 
the inhibition of the gene resulted in suppression of tumour growth (Fang et al., 1999). In 
addition, MMPs have been shown to act anti-angiogenically through the cleavage of 
plasminogen resulting in the generation or release of an angiogenesis inhibitor, angiostatin, 
from the ECM (Cornelius et al., 1998). More recent studies in animal models showed that 
synthetic and endogenous MMP inhibitors reduced tumour angiogenesis (Li et al., 2001; Oh et 
al., 2001; Xu et al., 2001). 
             
 1.3.3.6 Matrix metalloproteinase 2 expression in cancer 
Matrix metalloproteinase 2 expression has been investigated in several studies. In oesophageal 
cancer, MMP2 activation has been associated with lymph node metastasis and vascular 
invasion (Koyama et al., 2000; Shima et al., 1992). Polymorphisms in the MMP2 promoter 
regions are reported to be a genetic susceptibility factor for the occurrence and metastasis of 
oesophageal carcinoma (Yu et al., 2004).  The overexpression of MMP2 has been associated 
with a shorter survival in breast cancer, metastatic invasion in ovarian, prostratic and lung 
cancer, as well as an aggressive phenotype of pancreatic cancer (Bramhall et al., 1996; 
Fishman et al., 1996; Stearns and Stearns, 1996; Talvensaari-Mattila et al., 1998; Tokuraku et 
al., 1995).  
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Inactivation of MMPs by either overexpression of TIMPs or administration of synthetic MMP 
inhibitors may prevent initiation of MMP activation cascades, and regulate ECM degradation 
(Brown, 1999). Currently several synthetic inhibitors of MMPs are being tested in clinical 
trials for several types of cancer (Baker et al., 2002; Brown, 1999; Hoekstra et al., 2001). 
Unpleasant side effects have been a problem due to the broad substrate specificity.  
 
1.3.4 Gene expression studies in OSCC 
The current knowledge of genes and pathways involved in the process of OSCC 
tumourigenesis is limited. Previous studies on OSCC have investigated the molecular 
alterations present in aberrant cell cycle control, DNA repair, cellular enzymes, growth factor 
receptors, and nuclear receptors (Lam et al., 2000). Differential gene expression is one of the 
important mechanisms of pathogenesis in human diseases. Variations in expression include 
altered levels of normal gene products as well as modified proteins resulting from mutations. 
Detection of differential expression during early pathogenesis may help elucidate the 
underlying mechanisms of carcinogenesis and suggest therapeutic approaches. Real time PCR 
technology can now be used to detect variant gene expression. 
 
1.4 Study Objectives 
The aim of this study therefore, was firstly, to validate a novel real time PCR probe gene 
expression system by comparison with existing fluorescent technology, and secondly, to 
determine levels of expression of particular genes known to be associated with OSCC using 
real time PCR technology.  
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The specific aims of the study were: 
 
1. To validate a novel real time PCR probe system by comparison with existing fluorescent 
dye technology. 
 
2. To evaluate gene expression quantification strategies by the comparison of two different 
relative quantification methods, namely a standard curve method and the Pfaffl model. 
 
3. To determine the gene expression of HER1, HER2, VEGF-A and MMP2 in surgically 
classified normal and tumour tissue of the oesophagus. 
 
4. To correlate gene expession data with patient survival, and clinical and histological 
information (where available). 
 
5. To evaluate the tissue sampling method used in this study for gene expression analysis. 
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Chapter 2: Methods and Materials 
 
2.1 Introduction to Methods 
Real time PCR methods using a universal probe library system (UPL) and SYBR Green I 
technology were used in this study to determine the gene expression of four genes known to be 
associated with oesophageal cancer. These genes were HER1, HER2, VEGF-A and MMP2. 
VEGF-A in this study will be referred to as VEGF. The gene for gylceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as the reference gene.  A brief overview on the sequence 
of methodologies utilised in this study is shown in Table 2.1, followed by a review on the 
principles of real time PCR technology. 
 
Table 2.1 Summary of procedures used in this study to quantitate expression of genes 
associated with oesophageal cancer. 
 
 
1) Extraction and quantification of RNA from oesophageal tissue. 
 
2) Reverse transcription of RNA (cDNA synthesis). 
 
3) Real time PCR to determine the relative expression of the VEGF gene using a standard curve 
method and SYBR Green I technology in order to compare real time PCR detection systems. 
 
4) Real time PCR to determine the relative expression of the VEGF, HER1, HER2 and MMP2 
genes using a standard curve method and novel universal probe library (UPL) technology. 
 
5) Real time PCR using the Pfaffl model to determine the relative expression of firstly, the VEGF 
gene using the SYBR Green I system, and secondly, all 4 genes using UPL technology, in order 
to compare relative gene expression quantification methods. 
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2.1.1 Polymerase Chain Reaction 
The amplification of RNA and DNA has conventionally been performed by the polymerase 
chain reaction developed by Kary Mullis in the 1980s. This technology allows more than a 
billion fold amplification of DNA (Mullis and Faloona, 1987; Mullis, 1990). Each cycle of the 
PCR theoretically doubles the amount of DNA targeted by the primers in the reaction. A 
typical amplification reaction includes the target DNA, a thermostable DNA polymerase, two 
oligonucleotide primers which flank the sequence of interest, deoxynucleotide triphosphates 
(dNTPs), reaction buffer and magnesium chloride (MgCl2). The initial step of the 
amplification reaction denatures the target DNA by heating to 94̊C or higher for 15 seconds 
to 2 minutes. The helical DNA strands separate from each other to yield single stranded DNA 
template for replication by thermostable DNA polymerase (Figure 2.1). In the second step of 
the cycle, the temperature is reduced to approximately 40-60˚C so that the oligonucleotide 
primers can form stable associations (anneal) with the denatured target DNA and serve as 
primers for DNA polymerase. This step lasts approximately 15 to 60 seconds. In the final step, 
the addition of dNTPs by DNA polymerase initiates the synthesis of new DNA strands. The 
reaction temperature is raised to 70 to 74̊C for the DNA polymerase to work optimally. The 
extension step lasts approximately 1 to 2 minutes and the next cycle begins with a return to 
94˚C for denaturation. Figure 2.1 below is an illustrative summary of the steps involved in a 




Figure 2.1 Schematic representation of the Polymerase Chain Reaction. 
 
2.1.2 Real Time PCR 
The analysis of PCR products during the amplification procedure is known as ‘real time PCR’ 
(Meuer et al., 2001). The amount of double stranded PCR product is monitored at each cycle 
by means of fluorescence and is plotted against cycle number, to allow the visualisation of the 
accumulation of PCR products, as shown in Figure 2.2 (Meuer et al., 2001).  
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Figure 2.2. A typical PCR amplification curve (Roche Applied Science, 2003). 
 
The first phase of a real time PCR amplification reaction is the assessment of background 
fluorescence. The second phase is an exponential linear amplification of the product which is 
reflected as a sharp increase in fluorescence that can be detected above background. Lastly 
there is a plateau phase which is defined as the attenuation in the rate of exponential product 
accumulation (Kainz, 2000). The point at which the fluorescent signal significantly rises above 
background is known as the threshold cycle (Ct) and always occurs during the exponential 
phase of amplification (Bustin, 2000).  
 
Theoretically the PCR is described by the formula,  
Nn = N0 x 2
 where N represents the number of amplified molecules and n, the number of amplification 
cycles (Roche Applied Science, 2003). ). Efficiency is assumed to be optimal and constant in 
this reaction, in which every PCR product is replicated once every cycle.  
n 
 46 
This, however, may not be the case in reality since many factors influence the PCR and the 
efficiency may not always be optimal. A more accurate representation of the PCR 
amplification is expressed by the following equation,  
Nn= N0 x (E const.)
whereby E represents PCR efficiency. In the final phases of the PCR, the exponential curve 
bends towards a plateau and the efficiency becomes variable making it difficult to obtain 
accurate measurements during these last stages. This occurs with conventional PCR, where 
DNA is amplified and detected at the ‘end point’ of an amplification curve and there is no 
direct relation of DNA input to amplified target (Kainz, 2000). Additionally, measurements 
taken at the end-point of a PCR cannot easily distinguish variations in the amount of starting 
material or amplification efficiency. Reactions with low initial copy number can reach the 
same plateau as reactions with higher initial template concentrations and/or different PCR 
efficiencies, as seen in Figure 2.2. (Roche Applied Science, 2003). Real time PCR allows for 
more accurate measurements as quantification is extracted in the log-linear phase of the 
amplification curve where the amplification efficiency of each reaction is constant (Roche 










2.1.3 Real time PCR instrumentation 
The real time instrument used in this study was the Lightcycler (Roche Diagnostics, 
Mannheim, Germany) which consists of three parts: a sample carousel, thermal chamber and 
fluorimeter component.  The sample carousel is centrally positioned within the cylindrical 
thermal chamber and holds 32 glass capillaries, which serve as cuvettes for flourimetric 
analysis. The glass capillaries contain a reaction volume of 10-20µl with a surface-volume 
ratio to allow rapid thermal transfer within the reaction solution, thus ensuring efficient 
temperature transitions during PCR cycles (Roche Molecular Biochemicals, 2000). The 
thermal chamber contains a temperature sensor near the glass capillaries to measure and 
control the temperature within the chamber. Optimal homogenous air temperature is 
moderated by a blower that consists of separate heating coils located at the base of the thermal 
chamber and a high velocity fan, which evenly distributes incoming air throughout the 
chamber. A vent at the side of the chamber releases surplus air. The fluorimeter is directly 
connected to the thermal chamber by the optical system. The optical component consists of a 
blue light emitting diode (LED) for fluorophore excitation energy, a stepper motor for the 
rotation of glass capillaries to a specific position for excitation and measurement, as well as 
dichroic mirrors that divert light from the capillaries into detection channels.  The detection 
channels are composed of combination filters to detect fluorophores at various emission 
wavelengths, allowing for multiple colour detection and application flexibility (Roche 
Molecular Biochemicals, 2000). Data are displayed on a computer screen for real time 





2.1.4 Real time PCR chemistries 
At present there are four well established methods to detect amplicons with similar sensitivity 
(Wittwer et al., 1977). The simplest method utilises fluorescent dyes, such as SYBR Green I, 
that bind specifically to double stranded DNA (Morrisson et al., 1998). Other methods such as 
molecular beacons, hybridisation probes and hydrolysis probes, rely on the hybridisation of 
fluorescence-labelled probes to a specific amplicon (Bustin, 2000). Each system has unique 
features but all employ a change in the intensity of fluorescence to determine DNA 
amplification. The two methods discussed here are fluorescent dyes and hydrolysis probes. 
 
2.1.4.1 SYBR Green I 
SYBR Green I dye emits little fluorescence in solution but when bound to the minor groove of 
double stranded DNA, it releases a one thousand fold greater fluorescence. An increase in 
fluorescence reflects an increase of double stranded DNA (Bustin, 2000). Prior to 
amplification, the reaction mixture contains the denatured DNA, primers, and dye. The 
unbound dye molecules fluoresce weakly, producing a minimal background fluorescence 
signal which is subtracted during analysis. After the primers have annealed, some dye 
molecules bind to the short double strand DNA sequence, resulting in increase in the 
flourescence of SYBR Green I molecules. During the elongation step of the PCR additional 
SYBR Green I molecules bind to the newly synthesised DNA and an increase in fluorescence 
is seen in real time. On denaturation of the DNA in the next heating cycle, the dye molecules 
are released and the fluorescence signal falls (Wittwer et al., 1977). As DNA binding dyes do 
not bind specifically, this type of analysis is more likely to detect non specific fluorescence.  
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The dissociation curve (melt curve) of the amplified product is analysed in order to determine 
the melting point (Tm) of that product. The presence of two or more peaks implies that 
amplification was not specific for a single DNA target (Valasek and Repa, 2005).  
 
2.1.4.2 Universal probe library 
The universal probe library (UPL) system was developed by a Danish company, Exiqon, in 
2004. Sets of probes have been made available for genomes of various species, including 
human (Mauritz et al., 2005). The UPL consists of 90 short pre-validated probes that provide 
genome wide coverage.  The probe library design is based on particular 8- to 9-mer sequence 
motifs that appear with very high frequency throughout the whole genome (Mauritzen et al., 
2005). Ninety percent of all transcripts in the Ensemble human gene database which are based 
on exon-exon splice junctions, are targeted by the library probes, as are 99% of all transcripts 
recorded in the human gene RefSeq database at the National Center for Biotechnology 
Information (NCBI) (Mauritz et al., 2005). 
In comparison to conventional DNA probes which are normally 20 to 25 nucleotides in length 
and target specific sequences, UPL probes are limited to only 8 or 9 nucleotides which can 
target many different transcripts (Mauritzen et al., 2005). Adequate duplex stability and 
compatibility in standard real time PCR assays is ensured by the substitution with the high 
affinity DNA analogue, locked nucleic acid (LNA) (Mauritz et al., 2005). This novel nucleic 
acid analogue enhances hybridisation and stability, and also increases base-pairing specificity 
of the probes relative to DNA (Hertoghs et al., 2003. Thus the combination of the gene 
specific PCR primers and the UPL probe, results in a highly specific assay (Mauritzen et al., 
2005).  
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2.1.4.2.1 UPL primer and probe design 
The Assay Design Center software (www.probelibrary.com) is incorporated into the probe 
library package to allow for the selection of sequence specific probes and primers from the 
Probe Library for a given target (Mauritzen et al., 2005). The probe finder software identifies 
exon-exon boundaries from the given sequence and designs intron-spanning amplicons for the 
real time assay (Mauritzen et al., 2005). Intron recognition by the software is based on either 
an intron prediction algorithm following a Basic Local Alignment Search Tool (BLAST) 
search of target transcript against relevant genome sequence, or reference to the Ensemble 
database of target sequence (Mauritzen et al., 2005).  After intron site detection, the software 
searches the target sequence for sites complementary to UPL probes and generates possible 
probes for use in the assay. Potential primers are moderated by an in silico PCR algorithm that 
explores the genome and transcriptome sequences to guarantee a high measure of specificity 
(Mauritzen et al, 2005).  
2.1.4.2.2 UPL performance 
Functional assays performed for 96% of 175 RefSeq transcripts without any optimisation 
strategies have demonstrated a PCR efficiency of 100% using LinRegPCR software 
(Mauritzen et al., 2004; Ramakers et al., 2003). Time and cost spent on assay optimisation can 
be avoided by replacing an inadequately performing assay with another assay from the 
probefinder software list (Mauritzen et al., 2005). Experiments comparing Hyb-Probes, SYBR 
Green I and UPL probes were also undertaken and showed that crossing point values for 
SYBR Green I were lower than those of the UPL and Hyb-probe assays due to the higher 
specificity of the probe based assays (Mauritzen et al., 2005).   
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2.1.4.2.3 UPL Assay 
Hydrolysis probes are also called 5’-nuclease probes and consist of two types of fluorophores: 
reporters and quenchers. The reporter dye is usually a long-wavelength coloured dye, and is 
attached to the 5´ end of the probe, whereas the quencher dye is normally a short-wavelength 
coloured dye attached to the 3´ end (Mauritz et al., 2005). When the probe is either attached or 
unattached to the template DNA, or attached but prior to the action of the Taq polymerase, the 
quencher fluorophore absorbs the fluorescence from the reporter
 
 fluorophore through 
fluorescence resonance energy transfer, also called Főrster transfer (Mauritz et al., 2005). 
After the addition of nucleotides, cleavage of the reporter dye by Taq polymerase occurs 
resulting in an increase in fluorescence, which is quantified by the analysis software. The total 
fluorescence detected is proportional to the amount of specific DNA present. 
2.1.5 Real time PCR relative quantification strategies 
Relative quantification associates the PCR signal to an input copy number by using a standard 
curve (calibration curve). Serial dilutions of an external standard with a predefined known 
concentration are used to create a standard curve which then allows for the determination of 
unknown sample concentration on the basis of the cycle threshold (Ct) value (Wong and 
Medrano,  2005).  The amplification efficiency is assumed to be equal for both standards and 
samples. With this kind of relative quantification, the quantity of the unknown sample is 
determined using a standard curve and then expressed relative to the reference gene (Livak 
and Schmittgen, 2001). Commonly used reference genes are so-called housekeeping genes 
that are vital for normal cell function and believed to have stable expression. These include the 
genes for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ß-actin and ribosomal RNA 
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(rRNA) (Wong and Medrano, 2005). The optimal reference gene should not be regulated 
under experimental conditions, as a stable and constant reference is vital for normalisation.  
 
It has been shown that the expression level of some housekeeping genes varies according to 
biological material type or conditions (Bustin, 2000). Care should therefore be taken when 
selecting a housekeeping gene for relative quantification. 
 
Relative quantification can also be calculated without a standard curve, in which case, 
concentrations of the target and reference gene are a function of amplification efficiency 
(Wong and Medrano, 2005). The efficiency of the PCR is an important factor in quantification 
strategies as the assumption is that of an ideal efficiency, in which the PCR product doubles 
during the exponential phase of every cycle of the reaction (Liu and Saint, 2002). However in 
reality, PCRs do not have ideal efficiencies so that calculations without correction for 
efficiency result in less accurate quantification values (Liu and Saint, 2002). In addition, the 
efficiency of a reaction calculated from the data of a standard curve does not take into account 
the change in the efficiency during the reaction. Each reaction is relatively stable in the early 
exponential phase but slowly deteriorates to zero as the reaction progresses, due to a number 
of factors such as, depletion of PCR elements, degradation of polymerase enzyme activity and 






There are several mathematical models based on PCR kinetics that endeavour to accurately 
quantify relative gene expression with efficiency correction. One such model is that of Pfaffl 
et al., (2002) which incorporates gene quantification and normalisation into a single equation: 
Ratio = (Etarget)∆CP target (control-sample)/ (Eref)
This equation quantifies the relative expression of a target gene (target) in comparison to a 
reference (ref) gene by using crossing points (CP), PCR efficiencies (E) and the difference (∆) 
between an unknown sample versus a control (∆CP 
∆CP ref (control-sample) 
control-sample). The relative expression 
software tool (REST©) which runs on Microsoft® Excel and employs the Pairwise Fixed 
Reallocation Randomization Test©
 
, was used to calculate significance of the results (Pfaffl et 
al, 2002). In this study, relative gene expression was calculated using the Pfaffl model (Pfaffl 
et al, 2002), as well as the standard curve method in order to compare the two quantification 
strategies. 
2.2 Patients and specimens 
A randomly selected cohort of 30 patients who had undergone oesophagectomies at the 
Department of Cardio-Thoracic Surgery, Inkosi Albert Luthuli Central Hospital (IALCH), 
Durban, KwaZulu-Natal (KZN), were enrolled into the study. Tumour and normal tissue 
classified into cancerous and non-cancerous regions during surgery, were frozen at -70˚C after 
collection. Additional clinical data were supplied by the Department of Cardio-Thoracic 
Surgery, IALCH, KZN. Histological assessment of samples was performed by the Department 
of Anatomical Pathology, IALCH, KZN. 
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The patient cohort was divided into two groups designated A and B. Group A comprised the 
original 30 patient cohort and group B comprised a 22 patient sub-cohort of group A, which 
consisted of the original 30 patient cohort less 8 patients who were removed following a 
retrospective assessment of samples. This is discussed in detail in sections 2.9 and 3.6. Gene 
expression analyses and histological assessment were performed on both groups in order to 
evaluate the effect of the sample classification method.  
 
The histological assessment was carried out on groups A and B, but 3 patients had unavailable 
clinical data and thus complete assessment was carried out on 27 and 19 patients, respectively. 
In group A there were 17 females and 10 males who had a mean age of 57.2 years and range 
of 33–78 years. A more detailed demographic profile is shown in Figure 3.6 in Chapter 3. 
 
2.3 Ethics 
Ethical approval was granted for this study on the 08/10/2004 by the Biomedical Research 
Ethics Committee, UKZN, reference no: H147/04.  
 
2.4 RNA preparation 
High quality RNA is essential for successful real time PCR. To achieve this, the RNA must be 




Paired samples of tumour and normal oesophageal tissue from each patient were collected at 
resection from the Department of Cardio-Thoracic surgery, IALCH and frozen at -70˚C until 
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use. The tissue was allowed to thaw on ice and RNA was extracted using the TRIZOL method 
with minor modifications to improve the yield of RNA (Perou et al., 1999). The method is 
described in Appendix C. 
 
2.4.2 Purification 
The isolated RNA was purified and treated for possible DNA contamination using the Aurum 
Total RNA mini kit (Biorad, catalog number 7326820) according to the manufacturer’s 
instructions with minor modifications as described in Appendix D. Any DNA contamination 
can result in inaccurate RNA quantification and erroneous levels of PCR products.  
 
2.4.3 Electrophoresis 
The quality of RNA samples was assessed on a denaturing MOPS gel (Appendix F). The 18S 
and 28S subunits of RNA were visualized under ultraviolet radiation at a wavelength of 
300nm using the Chemidoc UV transilluminator. This procedure was carried out to confirm 
that the RNA was not degraded and was of sufficiently good quality for use in real time PCR. 
The gel image was scanned electronically and the Quantity One V.4.4.1 software was used to 
adjust the light and contrast of the image before printing. 
 
2.4.4 Quantification 
Quantification of RNA was performed in triplicate using a Nanodrop ND-1000 UV/Vis 
Spectrophotometer at 260 nm, according to manufacturer’s instructions (Nanodrop 
Technologies Inc., Washington, USA). The purity and concentration of the sample was 
calculated by on-board software. The RNA was required to have a 260/280 nm ratio reading 
ranging from 1.8- 2 to ensure the purity of the sample. 
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2.4.5 Storage of RNA 
The isolated RNA samples were aliquoted into 20µl volumes and stored at -70˚C until use. 
 
2.4.6 Reverse transcription 
One microgram of total RNA was subjected to reverse transcription using the iScript cDNA 
synthesis kit (Biorad), according to the manufacturer’s instructions. The GeneAmp 9700 PCR 
system (Applied Biosystems, California, USA) was used to carry out the reverse transcription 
reaction. The products were verified by performing a GAPDH PCR as described below. The 
remaining cDNA was stored at -20˚C until use. 
 
2.5 GAPDH PCR 
The GAPDH PCR was performed to confirm successful reverse transcription. In addition, 
since primers were designed to include an intronic region, the presence of any contaminating 
genomic DNA would be easily detected since contaminated cDNA would yield a larger 
product size than the expected 250 bp cDNA product. The GAPDH primers were synthesised 
by Roche Diagnostics (Mannheim, Germany): 
5´AAG GTC GGA GTC AAC GGA TT 3´ (forward) 
5´ CTC CTG GAA GAT GGT GAT GG 3´ (reverse) 
A PCR core kit (Roche Diagnostics) comprising of 10x PCR reaction buffer that consisted of 
100mmol/l Tris-HCl, 15mmol/l MgCl2 and 500mmol/l KCl, dNTP mix and Taq DNA 
polymerase was used. The final reaction volume was 25µl and the reaction mix comprised 
2.5µl of 10x PCR reaction buffer, 0.5µl dNTP mix (10mmol/l), 0.15µl Taq DNA polymerase 
(5U/µl), 1µl of each primer (200nmol/l), 16.85µl sterile water and 3µl cDNA template. The 
GeneAmp 9700 PCR system was used to carry out the PCR reaction.  
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The initial denaturation was at 95ºC for 5 minutes followed by 35 cycles at 1 minute. Primers 
annealed at 64̊ C for 30 seconds and extension occured at 72˚C for 30 seconds followed by a 
final extension at 72̊C for 10 minutes. Genomic DNA used as a positive control and sterile 
water was substitituted for cDNA as a negative control. The products were verified on agarose 
gel electrophoresis as described in Appendix E. 
 
2.6 Real Time PCR using SYBR Green I 
SYBR Green I technology was used in the generation of amplicons for the construction of 
standard curves.    
 
2.6.1 Optimisation of PCR conditions 
Factors such as annealing temperatures, primer and MgCl2
 
 concentrations and cycling 
conditions were optimised for each gene examined. All optimisations were carried out using 
the Faststart DNA Master SYBR Green I kit (Roche Diagnostics) on the Roche Lightcycler.  
Primer titrations to determine the most favourable primer concentration for each gene (HER1, 
HER2, VEGF, MMP2 and GAPDH) were performed using primer concentrations decreasing 
from 1000nmol/l to 10nmol/l. A primer concentration of 20nmol/l was found to be optimal for 
all genes with the SYBR Green I system. Magnesium titrations were also carried out for all 
genes (HER1, HER2, VEGF, MMP2 and GAPDH), using a MgCl2 gradient of 1.5, 3, 4.5 and 
6mmol/l to determine the optimal MgCl2 concentration for each gene. The optimal MgCl2
 
 
concentration for all genes was found to be 3mmol/l. 
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The optimised PCR conditions for the GAPDH gene were: denaturation at 95̊C for 1 minute 
followed by 45 cycles comprising denaturation at 95̊C for 5 seconds, annealing at 65˚C for 6 
seconds, elongation at 72˚C for 6 seconds, and a further extension at 83˚C for 10 seconds. The 
melt curve segment comprised of 1 cycle of 95˚C for 30 seconds, 70˚C for 10 seconds and 
95˚C for 0 seconds. Finally the PCR was cooled for 1 cycle at 40˚C for 30 seconds. Cycling 
conditions similar to those used for GAPDH were used for all the genes, with some 
modifications. The primer annealing temperature for VEGF, HER1, HER2 and MMP2 was 
58˚C.  The further extension step for HER1 and HER2 was carried out at 80˚C for 6 seconds.  
The increased temperature for the further extension step melts the non specific PCR products 
and eliminates the non specific fluorescence signal resulting in an enhanced accurate 
quantification of the desired real time PCR products. 
 
2.6.2 Templates for standard curves 
After optimising the magnesium and primer concentrations for each gene, cDNA amplicons 
were generated for each gene using the optimised PCR conditions. The concentration of 
amplified cDNA was calculated on triple readings, using the Nanodrop spectrophotometer on 
a cDNA setting. The mean concentration and mean absorbance at 260nm were used to 
calculate number of molecules using the following series of calculations (Roche Diagnostics):  
 
Number of molecules of amplified DNA = number of moles of DNA (n) x Avogadros 
number (6.022 x 1023
[MW of ds DNA = number of base pairs of DNA x average mass of base pair (660DA) and 
GM = absorbance at 260nm x concentration (ng/µl)/1000 = µg] 
), where n = concentration of double stranded DNA (GM)/ Molecular 
weight of ds DNA (MW)  
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These PCR products were then stored at -20˚C until used as templates to create standard 
curves with both the UPL and SYBR Green I systems. 
 
2.6.3 Relative gene expression of VEGF and GAPDH using SYBR Green I 
Standard curves were created for the VEGF and GAPDH genes by carrying out real time PCR 
on ten fold serial dilutions of the respective PCR products. The Lightcycler Faststart DNA 
Master SYBR Green I kit (Roche Diagnostics) was used for these reactions. The normal and 
tumour samples from each patient were then analysed under the optimised SYBR Green I 
conditions (section 2.6.1) with any two standards/calibrators from the corresponding 
previously constructed standard curves. 
 
The Lightcycler Faststart DNA Master SYBR Green I kit (Roche Diagnostics) was used for all 
of these reactions. The second derivative maximum setting was used to calculate the absolute 
gene expression of the samples by comparison with the standard curves that were created. The 
absolute VEGF gene expression in each sample was normalised by dividing by the 
housekeeping gene (GAPDH) expression value, in order to obtain a relative gene expression of 
VEGF for each sample. 
 
 
2.7 Relative gene expression using UPL technology 
Various nucleic acid sequences, particularly reference sequences, of each gene were selected 
from the NCBI using BLAST. The sequences were then compared and aligned using Bioedit 
which identifies conserved regions of target genes (Appendix G).  
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Probes and primers for these sequences were manufactured by Roche Diagnostics using the 
Assay design software (www.probelibrary.com) and the Probefinder software V2.04 which 
identifies and designs appropriate primer and probes for the target gene sequence. Primers 
were stored at a concentration of 1000nmol/l and probes at a concentration 500nmol/l, at -
20°C (Appendix G).  
Standard curves for HER1, HER2, VEGF, MMP2 and the housekeeping gene GAPDH were 
created using ten fold serial dilutions of their PCR products (section 2.6.2). At least 7 dilutions 
were used from the dilution series to ensure that samples with low gene expression fell into the 
range of the standard curve. The Lightcycler Taqman Master kit (Roche Diagnostics) was used 
to carry out the real time PCR. The total reaction volume was 20µl, comprising 4µl Taqman 
master, 0.2µl of each primer (200nmol/l), 0.2µl of the respective probe (100nmol/l), 10.4µl 
sterile water and 5µl of template.  
 
The PCR mixture was incubated at 95˚C for 10 minutes, followed by 30 cycles of denaturation 
at 95˚C for 10 seconds, annealing at 60˚C for 30 seconds, extension at 72˚C for 1 second and 1 
cooling cycle at 40̊ C for 30 seconds (Roche Diagnostics). The on -board lightcycler software 
(V.3.5) performed all analytic calculations using a software algorithm that identifies the first 
turning point of the fluorescence curve which serves as the crossing point (CP). In this study 





The normal and tumour samples from each patient were analysed with two 
standards/calibrators from the corresponding previously constructed standard curves for each 
of the 5 genes. The absolute gene expression of all 5 genes in each sample was obtained by 
comparison to the external standard curves that were created. The absolute gene expression 
values of all genes (VEGF, HER1, HER2, MMP2) in each sample were normalised by dividing 
these values by the housekeeping gene (GAPDH) expression values, in order to obtain the 
relative gene expression of each gene in each sample. 
 
2.8 Relative gene expression using the Pfaffl model 
As previously described, according to the Pfaffl model (Pfaffl et al., 2001), the relative 
expression ratio of a target gene is based on real time PCR efficiency and the crossing point 
deviation of an unknown sample compared with a control. This method does not require a 
standard curve. Efficiency curves for each gene (HER1, HER2, VEGF, MMP2 and GAPDH) 
were created with the UPL system and appropriate cycling conditions (section 2.7).  
 
The efficiency curve template was composed of 1µl of cDNA made up of a pooled mixture of 
all normal and tumour samples serially diluted (1300, 260, 130, 26, 13, 2.6, 1.3 ng), based on 
the method described by Pfaffl et al. (2002). Each PCR was carried out in duplicate. 
Efficiency curves were also created for VEGF and GAPDH using the SYBR Green I system 




2.8.1 Calculation of relative gene expression using REST©
Real time PCR efficiencies for each efficiency curve were calculated from the slope generated 
by the Lightcycler software. The corresponding real time PCR efficiency (E) of one cycle in 
the exponential phase was calculated according to the established equation E = 10
  
[-1/slope] 
(Rasmussen, 2001). The value of E ranges from 1 (minimum value) to 2 (theoretical maximum 
and optimum). Crossing points of normal and tumour samples for all genes using both the 
UPL and SYBR Green I systems were entered into the REST©
Calculated efficiencies for all efficiency curves were also entered into the REST
 Software database, as well as 
the calculated concentrations of pooled cDNA template and the corresponding CP for each 
gene on both UPL and SYBR Green I systems.  
© database. 
This database is a Microsoft Excel ® macro (Microsoft Corporation) attached to a purpose-
built spreadsheet running in the background of REST©. The relative expression ratio for all 
genes was quantified using the REST©
The group ratio results were tested for significance by using the pair wise fixed reallocation 
randomization test to analyse the differences in expression between reference and target genes. 
Randomisation tests made no distributional assumptions about the data. The p-values were 
calculated by obtaining the proportion of random allocations of the mean observed data to the 
reference and target genes. 
 software (section 2.1.5) on the basis of group means 





2.9 Histopathological assessment of oesophageal samples 
Clinicopathologic parameters of each tumour such as tumour type, size, histological grade, 
dysplasia, carcinoma in situ (CIS), necrosis, myenteric plexus and perineurial invasion, 
lymphatic vessel invasion, characteristics of tumour morphology (squamous keratin, anaplasia, 
atypical mitoses), mitotic rate, extent of tumour invasion, lymphatic node involvement and 
lymphocyte host response were assessed from Hematoxylin and Eosin (H&E) slides of the 
gross oesophagectomy specimen from each patient. The slides were viewed by both the 
pathologist and the investigator under a double headed Leitz Orthoplan microscope (Leica, 
Wetzlar, Germany). The relevant information was entered on to a histopathological proforma 
for correlation with gene expression data. 
All parameters were classified according to the American Joint Committee on Cancer (AJCC) 
staging manual (Greene et al., 2002), with a few exceptions. The mitotic rate was classified as 
≤ 50 or > 50. Mitotic figures were counted in 10 viewing fields with 400x magnification using 
a light microscope. The mitotic rate was taken as the fraction of cells that are in mitosis at any 
given time (Sadava, 1993). Regions with necrosis, inflammation and fibrosis were avoided as 
far as possible. Necrosis was stratified as mild (0-33%), moderate (34-66%) and extensive 
(>66%). Perineurial invasion was seen as the infiltration by cancer cells into the perineurium. 
The tissue sampling method used in this study was retrospectively assessed from the available 
samples after experimental work was completed in order to evaluate its accuracy. Histological 
verification was carried out on nineteen matched pairs of frozen normal and tumour 
oesophageal tissue at the Department of Anatomical Pathology, IALCH. Each frozen 
oesophageal tissue specimen was thawed and processed for H&E staining using standard 
methods (Bancroft and Cook, 2002).  
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This process was carried out by pathology technicians and observed by the investigator. After 
H&E staining, each sample was viewed under a double headed light microscope and assessed 
by the pathologist as to whether there was agreement or discordance between surgical and 
microscopic classification of ‘normal’ or ‘tumour’ tissue. Photographs of some specimens 
were taken using a digital camera. 
 
2.10 Statistical data analyses  
Due to the discrepancies found between the microscopic and surgical classification of normal 
and tumour tissue to be discussed in section 3.6, statistical data analyses were performed on 
two groups: A and B. As mentioned earlier and discussed in section 3.6, Group A comprised 
of the original 30 patient cohort and group B comprised a 22 patient sub-cohort following 
exclusion of 8 patients who had discordant clinical and histopathological data. All statistical 
data analyses methods were performed by a biostatistician using current methods in the 
literature. These will be described in more detail in the relevant sections.  
2.10.1 Analysis of relative gene expression 
Absolute gene expression values for the tumour and normal samples from each patient were 
generated by the Lightcycler software for each of the target genes: HER1, HER2, VEGF and 
MMP2. These values were normalised by dividing by the values obtained for the 
housekeeping gene (GAPDH) in order to obtain the relative gene expression values. 
Descriptive statistical analyses of the comparison between tumour and normal tissue for each 
patient and each gene were carried out using the Statistical Package for the Social Sciences 
15.0 (SPSS Inc. Chicago, IL). The tests used are described below. Unless otherwise stated, 
statistical significance for all tests was defined as p < 0.05.  
 65 
The Wilcoxon signed ranks test and a two-tailed p-test were used to compare the difference 
between the median values of matched tumour and normal tissue for each gene (Chiu et al., 
2005; Duraker et al., 2003; Hashimoto et al., 2005; Shih et al, 2000; Yu et al., 2005).  
 
For each patient, a gene was defined as upregulated if the tumour/normal gene expression ratio 
was >1. If this value was <1, the gene was defined as downregulated. For each gene, a median 
fold change for the cohort was calculated (Chiu et al., 2005; Duraker et al., 2003; Hashimoto 
et al., 2005; Shih et al, 2000; Yu et al., 2005). Comparison of the UPL system and SYBR 
Green I system was also carried out by using the Wilcoxon signed ranks test and two-tailed p-
test. The Chi-squared and McNemar tests (using binomial distribution) were used to calculate 
the level of discordance between the systems. All graphs were drawn using Graphpad Prism 
V.4 (Graphpad software Inc., CA, 2003) 
2.10.2 Correlation between clinicopathologic factors and gene expression 
The upregulation or downregulation of each gene (VEGF, HER1, HER2 and GAPDH), in each 
patient, was correlated statistically with important clinicopathologic factors (section 2.9) using 
the Chi-squared or Fishers exact test with SPSS (Chiu et al., 2005; Duraker et al., 2003; 
Hashimoto et al., 2005; Shih et al, 2000; Yu et al., 2005). 
2.10.3 Correlation of gene expression between genes 
The mRNA expression levels of each gene were analysed in relation with the levels obtained 
for every other gene, using correlation and linear regression analyses to determine if there was 
any relationship in gene expression between the target genes, VEGF, HER1, HER2 and MMP2 
(Chiu et al., 2005; Duraker et al., 2003; Hashimoto et al., 2005; Shih et al, 2000; Yu et al., 
2005). 
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Chapter 3: Results 
3.1 RNA preparation 
3.1.1 Isolation 
A representative gel illustrating isolated total RNA is shown in Figure 3.1. The integrity and 








Figure 3.1. Denaturing MOPS gel showing isolated total RNA. Lane M represents a RNA marker 
(RiborulerTM
M       N       1                2                  3                4                 5 
 RNA ladder, #SM1823, Fermentas Life Sciences, Lithuania), lane N is a negative control 
(water), lanes 1-5 are RNA bands corresponding to 4000 and 2000 bases. The quality of RNA is 
confirmed by the presence of 28S and 18S subunits of RNA. 
→ 28 S 
 







3.1.2 Reverse transcription 
A PCR of a segment of the GAPDH gene sequence was carried out to verify the efficacy and 
integrity of the reverse transcriptase reaction. A representative agarose gel showing the 225 bp 











Figure 3.2. Agarose gel showing the 225 base pair GAPDH PCR product obtained from cDNA 
samples in lanes 1-13. Lane (+): positive control, lane (-): negative ‘no DNA’ control and lane (M) 
shows the Marker (O’Range Ruler TM
M     -       +        1       2       3      4      5       6        7       8      9     10      12     13          





3.2 Real time PCR optimisation using SYBR Green I 
3.2.1 Primer titration 
A representative real time PCR melting curve profile for the HER2 and MMP2 genes is shown 
in Figures 3.3 and 3.4. The graphs depict primer titrations using SYBR Green I dye. The 
primer concentrations tested ranged from 10 to 1000nmol/l. A primer concentration of 
20nmol/l was selected for all genes (HER1, HER2, VEGF, MMP2, GAPDH) because of the 
absence of non specific amplification products, such as primer dimers, at this primer 
concentration, and to allow standardisation of the reaction conditions for all genes. 
 
 
Figure 3.3. Primer titration melting curve analysis for HER2 amplification products with SYBR Green 
I dye. The graph shows the negative derivative of fluorescence plotted against temperature. Non 




Figure 3.4. Primer titration melting curve analysis for MMP2 amplification products with SYBR 
Green I dye. The graphs show the negative derivative of fluorescence plotted against temperature. 
Graph A demonstrates the different primer concentrations tested with 20nmol/l and 100nmol/l being 
the most efficient concentrations. Graph B indicates the specificity of the amplification reaction at the 
chosen optimal primer concentration (20nmol/l) as represented by a single peak with a melting 
temperature (Tm) of 83.9˚C. 
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3.2.2 Magnesium chloride titration 
Figure 3.5 shows a representative real time PCR melting curve profile for the MMP2 PCR 
products obtained with different MgCl2 concentrations using the SYBR Green I detection 
system. The MgCl2 concentrations ranged from 1.5mmol/l to 6mmol/l. The most efficient 
standardised MgCl2 concentration was shown to be 3mmol/l for all genes (HER1, HER2, 
VEGF, MMP2, GAPDH) based on the efficiency of the amplification reaction and the absence 
of non specific amplification products. 
 
Figure 3.5. MgCl2 titration melting curve analysis for MMP2 amplification products with SYBR 
Green I dye. The graphs show the negative derivative of fluorescence plotted against temperature. 
Graph A shows non specific amplification products at the various MgCl2 concentrations and graph B 
shows 3mmol/l MgCl2 concentration to be the most efficient. 
 71 
3.3 Relative gene expression of VEGF and GAPDH using SYBR Green I  
Real time PCR with the SYBR Green I system was used to create standard curves for the 
GAPDH and VEGF genes. As mentioned previously in section 2.6.2, standard curves 
comprised serial dilutions of amplified PCR products as a standard template. The number of 
molecules of amplified product was calculated and dilutions of the amplicon, in duplicate, 
were performed on order to construct the standard curve for each gene (GAPDH and VEGF). 
Standard curves were generated by plotting the logarithmic concentration of the number of 
molecules against the cycle number at which the PCR product was initially detected (crossing 
point) as seen in Figure 3.6, A and B.   
 
Figure 3.6. Standard curves for GAPDH (A) and VEGF (B) using the SYBR Green I system. The 
standard curve was generated by plotting the crossing points (cycle number) of each standard against 
the logarithmic concentration. 
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The error value reflects tube to tube variations and should be lower than 10-1. The slope of the 
graph represents the overall reaction efficiency. For an optimal efficiency, the slope should be 
between -5.7 and -2.9 (Roche Molecular Biochemicals, 2000). The average efficiency of a 
PCR reaction was calculated as 10 -1/slope
The melting temperature (Tm) of the gene products are seen in Figure 3.7 and were found to 
be 86˚C and 83˚C for the GAPDH and VEGF products, respectively. The Lightcycler melting 
curve analysis for GAPDH and VEGF with the SYBR Green I system showed pure 
homogenous PCR products for each gene, as reflected by the single tight melting peak in 
Figure 3.7. Melting curves were converted to melting peaks by plotting the first negative 
derivative (-d(F1/F2)dT)) against temperature. 
. A theoretical efficiency of 2 suggests that 100% of 
the template is converted to product (Rasmussen, 2001). The efficiencies for each standard 
curve were calculated to be 1.58 for GAPDH and 2.02 for VEGF. 
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Figure 3.7. Melting peaks for PCR products of GAPDH (A) and VEGF (B). The melting temperature 
(Tm) of gene product which corresponds to the peak of the Gauss curve was 86˚C for GAPDH and 
83˚C for VEGF. 
The VEGF and GAPDH gene expression in tumour and normal tissue were quantified as 
illustrated in Figure 3.8. Standards from previously generated standard curves, as discussed 
above, were included in the real time PCR to quantify the respective gene expression in 
oesophageal tissue. Additionally, previously created standard curves were imported after the 
real time PCR was completed to allow the onboard Lightcycler software to calculate the 
respective gene expression in each sample. The data were then used for the statistical data 
analyses which are described in detail in section 3.7. 
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Figure 3.8. Real time PCR quantification of VEGF gene expression in normal and tumour 
oesophageal tissue samples using the standard curve method and SYBR Green I technology. Standards 
from previously constructed standard curves were used to quantify the VEGF gene expression in 
oesophageal tissue. 
 
3.4 Relative gene expression using UPL technology 
Standard curves for the GAPDH, VEGF, HER1, MMP2 and HER2 genes were generated using 
the UPL system. As mentioned previously in section 2.6.2, standard curves were produced by 
using serial dilutions of individual amplified PCR products as standard templates.  
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A significant increase in fluorescence above the baseline value indicated the detection of 
accumulated PCR product as illustrated in Figure 3.9 (A) for different dilutions of the gene 
product. Standard curves were generated by plotting the logarithmic concentration of the 
number of molecules against the cycle number at which the PCR product was initially detected 
(crossing point) as shown in Figures 3.9 (B), and 3.10 (A-D).  The average efficiency of the 
PCR reaction was calculated as described in section 3.3 and found to be 1.94 for GAPDH, 
2.04 for VEGF, 1.96 for HER1, 1.97 for HER2 and 1.65 for MMP2. 
 
 
Figure 3.9. Representative standard curves for the GAPDH gene using the UPL system. A. PCR of a 
dilution series of GAPDH amplicon was used as a standard template to construct an amplification 
curve. The exponential phase of the PCR is represented by the log linear segment of the curve. B. The 
standard curve was produced by plotting the crossing points (cycle number) of each standard against 
the logarithmic concentration.  
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Figure 3.10. Standard curves for the genes VEGF (A), HER1 (B), MMP2 (C) and HER2 (D) using the 
UPL system.  
Gene expression of the different genes in tumour and normal oesophageal tissue was 
quantified using standards from previous standard curves in the real time PCR, as illustrated in 
Figure 3.11 for the VEGF gene. Additionally, previously generated standard curves, as 
discussed above, were imported after the real time PCR was completed to allow the onboard 
Lightcycler software to calculate the respective gene expression in each sample. 
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Figure 3.11. A representative real time PCR quantification of VEGF gene expression in normal and 
tumour oesophageal tissue using UPL technology. Standards from previously constructed standard 
curves were included in the experiment in order to quantify the VEGF gene expression in oesophageal 
tissue. 
 
3.5 Relative gene expression using the Pfaffl model 
The Pfaffl model of relative expression of target genes is based on real time PCR efficiencies. 
Efficiency curves were constructed for GAPDH, VEGF, HER1, HER2 and MMP2 using the 
UPL system as illustrated in Figure 3.12, and for GAPDH and VEGF using the SYBR Green I 
system as shown in Figure 3.13.  
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Figure 3.12. Real time PCR efficiency curves for GAPDH (A), VEGF (B), HER1 (C), HER2 (D) and 
MMP2 (E) using the UPL system. The cycle number of crossing points was plotted against the log 
concentrations of cDNA (reverse transcribed total RNA) to calculate the slope. The corresponding real 






Figure 3.13. Real time PCR efficiency curves for GAPDH (A) and VEGF (B) using the SYBR Green I 
system. The cycle number of crossing points was plotted against the log concentrations of cDNA 
(reverse transcribed total RNA) to calculate the slope. The corresponding real time PCR efficiency was 
calculated using the equation: E = 10[-1/slope]
A pooled mixture of serial dilutions of cDNA of all normal and tumour oesophageal samples 
was used to create the efficiency curves, based on the method described by Pfaffl (2001) as 
described previously in Section 2.8.  The efficiencies of the curves calculated by the REST 
software after the input of CP values, were 1.85 for GAPDH using UPL, 2.11 for GAPDH 
using SYBR Green I, 2 for VEGF using UPL, 2.38 for VEGF using SYBR Green I, 1.89 for 
HER1 using UPL, 2.11 for HER2 using UPL and 1.88 for MMP2 using UPL. 
. 
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The REST software used the incorporated pair-wise fixed reallocation randomization test and 
Pearson’s correlation coefficient to generate relative expression ratios and p values, 
respectively, for the genes concerned as illustrated in Figure 3.14.  
 
Figure 3.14. Fold change of the relative gene expressions of VEGF, HER1, HER2 and MMP2 in 
oesophageal tumours for both groups A and B calculated using the Relative Expression Software Tool 
(REST) ©
The relative expression ratios were described as being up or down regulated and were 
calculated by the comparison of gene expression values in normal and tumour oesophageal 
tissue, on the basis of their group mean values and normalised by the GAPDH gene expression 
values (Pfaffl et al, 2002).  
 and the UPL system, and of VEGF using the SYBR Green I (SYBR) system. * indicates 
statistical significance of the differential gene expression of normal and tumour oesophageal tissue. 
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Upregulation in groups A and B was found to be 2.8 and 3.4 fold respectively, for VEGF using 
the UPL system, and 4.8 and 6.6 using the SYBR Green I system, 3.2 and 4 for HER1 using 
the UPL system, 3.6 and 4 for HER2 using the UPL system and 1.4 and 1.1 for MMP2 using 
the UPL system.  
The statistical significance of gene expression differences between normal and tumour 
oesophageal tissue for each gene were tested by the REST software using the Pearson’s 
correlation coefficient. The p values were calculated by obtaining the proportion of random 
allocations of the mean observed data to the normal and tumour samples (Pfaffl et al., 2002). 
Relative gene expression using the UPL system showed that the differential gene expression 
of normal and tumour oesophageal tissue was significantly upregulated in all genes, in group 
A and B (p = 0.001), except for HER1 in group B.  Differences in the VEGF gene expression 
of normal and tumour tissue was found to be insignificant in all samples with the UPL and 
SYBR Green I systems. 
 
3.6 Histopathological assessment of oesophageal samples 
 
Nineteen pairs of matched tumour and normal tissue from the 30 pair cohort were assessed by 
a pathologist and the investigator using a double-headed microscope (Appendix I). It was 
found that in 28 (73.7%) of the 38 specimens, there was agreement between the surgical and 
microscopic classification. Of these specimens: 
 
• 7 ‘normal’ specimens comprised deep oesophageal tissue (muscle) and fat.  Surface 
epithelium was not represented 
• 2 ‘tumour’ specimens contained very little tumour tissue (<10 cells) 
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In 10 (26.3%) of the 38 specimens, there was disagreement between the surgical and 
microscopic assessment. Of these specimens: 
 
• 5 ‘normal’ samples contained carcinoma (Figure 3.15) 
• 2 ‘normal’ samples were equivocal for carcinoma due to poor quality (Figure 3.16) 
• 2 ‘tumour’ samples did not contain tumour 












Figure 3.15. A and B, Histological section of visually classified ‘normal’ oesophageal tissue 
containing infiltrating tumour cells (arrow) (Sample 1 and 45) (H&E stain: original 







Figure 3.16. A. Degenerate oesophageal tissue (Sample 9, H&E stain: original magnification, 
x 120), B. Degeneration of oesophageal tissue due to freeze-thawing of sample (Sample 44, 
H&E stain: original magnification, x 240). 
 
The 10 specimens that were discordant with the original classification affected 8 matched 





3.7 Statistical evaluation of relative gene expression using the standard curve method 
 
As discussed previously in section 2.10.1, the relative gene expression values for each normal 
and tumour oesophageal sample was normalised by dividing by the respective housekeeping 
gene (GAPDH) values. The resulting values were the relative gene expression values for each 
gene in each sample. As discussed previously, two sets of data analyses were performed for 
the calculation of relative gene expression with the standard curve method. The first group 
designated A, included all 30 patients originally enrolled in the study. The second data set 
designated B, consisted of the 22 patients after the removal of 8 patients with discordant 
histology (refer to sections 2.10 and 3.6).  
 
3.7.1 Relative gene expression of oesophageal tumours 
The median relative expression data for all genes are presented in Table 3.1. The individual 











Table 3.1. The median relative gene expression values for normal and tumour oesphageal tissue 
obtained using the UPL and SYBR Green I systems. 
 Group A Group B 
Gene/GAPDH 
(UPL) 
Median values Median values 
VEGF Normal 0.01 0.18 
VEGF Tumour 0.27 0.34 
MMP2 Normal 350.09 247.38 
MMP2 Tumour 443.42 361.94 
HER1 Normal 0.47 0.04 
HER1 Tumour 0.10 0.12 
HER2  Normal 0.60 0.043 




VEGF Normal 0.0021 0.0024 
VEGF Tumour 0.0078 0.009 
 
The median relative gene expression values for tumours were generally higher than those in 
normal tissue for all target genes, except for HER1, as calculated with both the UPL and 
SYBR Green I systems. The relative gene expression values for MMP2 demonstrated a much 
higher range of values in comparison to the other genes. 
 
Box-whisker plots shown below represent a comparison between the relative gene expression 
median values for tumour and normal oesophageal tissue. The Wilcoxon signed ranks test for 
matched pairs (non parametric) was used to compare the relative gene expression between 
normal and tumour oesophageal tissue for each patient.  The Pearson’s correlation coefficient 
was used to test if differences in results between the two groups were statistically significant. 
Statistical significance was taken at the level of p < 0.05. 
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Figure 3.17. Box-whisker plots of the relative expression and variability in mRNA levels for 
the VEGF gene in normal and tumour oesophageal tissue in group A using UPL (A), group B 
using UPL (B), group A using SYBR Green I (C) and group B using SYBR Green I (D).  
* indicates statistical significance. 
 
The VEGF gene expression calculated using the UPL system was higher in tumour tissue 
compared with normal tissue for both data sets, but the differences were only of borderline 
significance. The VEGF gene expression in group B showed a smaller range of mRNA values 
in comparison with group A. The removal of discordant samples from group A removed those 
gene expression values that represented outliers. The relative VEGF gene expression as 
detected by the SYBR Green I system was significantly different in normal and tumour tissue 
for both groups A and B. 
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Figure 3.18. Box-whisker plots of the relative gene expression and variability in mRNA levels for:  
HER1 in group A (A), HER1 in group B (B), HER2 in group A (C), HER2 in group B (D),  MMP2 in 
group A (E) and  MMP2 in group B (F), in normal and tumour oesophageal tissue using the UPL 
system. * indicates statistical significance. 
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As seen Figure 3.18 above, the HER1 gene expression calculated using the UPL system was 
significantly higher in oesophageal tumours compared with normal tissue for both groups A 
and B. The HER2 and MMP2 gene expressions calculated with the UPL system were however, 
not significantly different between tumour and normal samples.  
3.7.2 Fold change of gene expression 
As discussed previously in section 2.10.1, the tumour/normal ratio (T/N) is an average fold 
change (increase or decrease) in the expression of a gene in the sample population. The T/N 
ratio of sample mRNA expression values was considered to be upregulated when T/N >1.0 
(tumour higher than normal) or downregulated when T/N < 1.0 (tumour lower than normal). 
The fold change values are illustrated in Figure 3.19 for each group studied and are 
represented by the median T/N values of normal and tumour oesophageal samples that are 
normalised by GAPDH.  
 
Figure 3.19. Fold change of the relative gene expression of VEGF in oesophageal tumours for both 
groups A and B using the SYBR Green I system (SYBR) and VEGF, HER1, HER2 and MMP2 using 
the UPL system and calculated using REST.  
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The fold change values in groups A and B were 3.6 and 4 for VEGF using UPL, 3 and 4 for 
VEGF using SYBR Green I, 2.9 in both groups for HER1 using UPL, 2.6 and 1.9 for HER2 
using UPL and 1.7 in both groups for MMP2. The VEGF gene displayed the highest fold 
change in comparison to the other genes analysed with this system, while MMP2 showed the 
least degree of upregulation in this cohort of patients.  
The percentages of individuals within each group whose tumours showed an increase or 
decrease in the frequency of gene expression relative to normal tissue are shown in Table 3.2. 
The majority of individuals showed upregulation of all four genes examined. 
Table 3.2. Frequency of fold change (Tumour/Normal) for all target genes in groups A and B. 






A. VEGF  70 30 
B. VEGF 72.7 27.3 
A. MMP2 63.3 36.7 
B. MMP2 63.6 36.4 
A. HER1 83.3 16.7 
B. HER1 90.9 9.1 
A. HER2 63.3 36.7 




A. VEGF 76.7 23.3 
B. VEGF 86.4 13.6 
 
3.7.3 Comparison between UPL and SYBR Green I systems 
Table 3.3 shows the comparison of the expression of VEGF in groups A and B as detected by 
the UPL and SYBR Green I systems. The chi squared and McNemar tests were used to 
examine the level of discordance between both systems. 
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Table 3.3. Comparison of the VEGF relative gene expression frequency between the UPL and SYBR 
Green I systems. 
 
  VEGF upregulation (%) VEGF downregulation (%) McNemar test (P) 
 Group A   Group B Group A   Group B  
VEGF UPL 70            72.7 30            27.3  
VEGF SYBR 76.7         86.4 23.3         13.6  
   0.688-Group A 
   0.250- Group B 
 
 
The percentage of VEGF upregulation was slightly higher using the SYBR Green I system 
than the UPL system, in both groups A and B but the differences were not statistically 
significant. Pearson’s correlation coefficient was used to compare the normal, tumour and fold 
change values between the UPL and SYBR Green I systems. The normal, tumour and fold 
change values were significantly different from each other when comparing the UPL and 
SYBR Green I systems in group A (Table 3.4). In group B, the normal and tumour were 
significantly different from each other but not the fold change values. However, the chi 
squared and McNemar tests calculated that the UPL and SYBR Green I systems were similar, 
overall, in their detection of gene expression. 
 
Table 3.4. Comparison of the VEGF relative gene expression in normal and tumour tissue and fold 
change value between the UPL and the SYBR Green I systems. 
 
VEGF expression P value (Group A) P value (Group B) 
Normal tissue (UPL) vs Normal tissue (SYBR) S (0.0) S(0.0) 
Tumour tissue (UPL) vs Tumour tissue (UPL) S(0.001) S (0.006) 
T/N (UPL) vs T/N (SYBR) S (0.015) NS 
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3.8 Histopathological and clinical assessment of patients with OSCC 
As mentioned previously (section 2.2 and 3.6), data evaluation was carried out on two groups: 
Group A comprised 30 patients and group B the remaining 22 patients after removal of 
discordant samples. For the histopathological analysis, 3 patients had no available clinical 
data. Therefore group A comprised 27 patients and group B, 19 patients. 
Photomicrographs of the histopathological features of OSCC that were analysed in the study 
cohorts are illustrated in Appendix J. The clinicopathological profile of patients and tumours is 
presented in Table 3.5. The mean age was 57.2 years for group A and 59.0 years for group B. 
The majority of patients had a tumour size of less than 5 cm and tumours were mostly 
moderately differentiated. Most patients had tumours that involved the adventitia and were 
positive for myenteric plexus invasion as well as perineurial invasion, and did not show lymph 
node involvement. Several patients however did not have lymph node tissue available for 
analysis. Dysplasia, carcinoma in situ and atypical mitoses were evident in the majority of 
patients. Mild necrosis (as well as anaplasia and a mitotic rate of less than 50 were seen in 
most patients. The majority of patients in group A showed lymphatic vessel invasion whereas 
most patients in group B did not exhibit lymphatic vessel invasion.  
 93 
Table 3.5. Patient and tumour characteristics of squamous cell carcinomas of the oesophagus. 
Factors Group A  Group B 
Mean age (yrs) 57.2 59 
≤50 yrs 6 (22.2%) 3 (15.8%) 
>50 yrs 21 (77.8%) 16 (84.2%) 
Gender ratio    
Male 10 (17%) 7 (36.85) 
Female 17 (63%) 12 (63.2%) 
Race ratio    
Black 21 (77.8%) 14 (73.7%) 
Indian 6 (22.2%) 5 (26.3%) 
Size of tumour   
< 5 cm 15 (55.6%) 11 (57.9%) 
≥5 cm 11 (40.7%)  7 (36.8%) 
unavailable 1 (3.7%) 1 (5.3%) 
Histological type   
Moderately differentiated 25 (92.6%) 18 (94.7%) 
Poorly differentiated 2 (7.4%) 1 (5.3%) 
Depth of Invasion (pT)   
Muscularis propria (pT2 1(3.7%) ) 1 (5.3%) 
Adventitia (pT3 25 (92.6%) ) 17 (89.5%) 
Adjacent structures (pT4 1 (3.7%) ) 1 (5.3%) 
Lymphatic node involvement   
(-) 12 (44.4%) 9 (47.4%) 
(+) 9 (33.3%) 6 (31.6%) 
Unavailable 6 (22.2%) 4 (21.1%) 
Myenteric plexus invasion   
(-) 1 (3.7%) 1 (5.3%) 
(+) 26 (96.3%) 18 (94.7%) 
Perineurial invasion   
(-) 3 (11.1%) 2 (10.5%) 
(+) 24 (88.9%) 17 (89.5%) 
Lymphatic vessel invasion   
(-) 6 (22.2%) 14 (73.7%) 
(+) 21 (77.8%) 5 (26.3%) 
Dysplasia   
(-) 1 (3.7%) 0 
(+) 26 (96.3%) 19 (100%) 
Carcinoma in situ   
(-) 10 (37%) 4 (21.1%) 
(+) 17 (63%) 15 (78.9%) 
Atypical mitoses   
(-) 12 (44.4%) 8 (42.1%) 
(+) 15 (55.6%) 11 (57.9%) 
Necrosis   
Mild (0-33%) 23 (85.2%) 16 (84.2%) 
Moderate (34-66%) 4 (14.8%) 3 (15.8%) 
Mitotic rate (no/10 HPF)   
≤ 50 23 (85.2%) 15 (78.9%) 
>50 4 (14.8%) 4 (21.1%) 
Anaplasia   
(-) 3 (11.1%) 1 (5.3%) 
(+) 24 (88.9%) 18 (94.74%) 
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3.8.1 Correlation between VEGF expression using UPL and clinicopathological factors 
The percentages of up and down regulation of VEGF expression determined using the UPL 
system, in relationship to clinical and pathological features, are represented in Table 3.6. In 
group A, VEGF upregulation was significantly associated with gender (p = 0.012) and race (p 
= 0.044): all black male patients displayed VEGF upregulation (raw data not shown). In group 
B (percentages not shown), VEGF expression was significantly associated with gender (p = 
0.044): all male patients displayed VEGF upregulation and most black patients displayed 
VEGF upregulation. Upregulation of VEGF was not significantly associated with age although 
most patients older than 50 years of age showed upregulation of this gene. The majority of 
patients with lymphatic node involvement, lymphatic vessel invasion, myenteric plexus 
invasion and perineurial invasion showed VEGF upregulation. In all pathological categories, 
the majority of tumours showed VEGF upregulation.  
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Table 3.6. Correlation between clinicopathologic variables and expression status of the VEGF 
gene. 
 Group A    
(n = 27) 
  Group B 
(n = 19) 
Factors VEGF↑ VEGF↓ P P 
Age   N.S. N.S. 
≤50 4 (66.7%) 2 (33.3%)   
>50 15 (71.4%) 6 (28.6%)   
Gender   S (0.012) S. (0.044)a a 
Male 10 (100%) 0   
Female 9 (52.9%) 8 (47.1%)   
Race   S (0.044) N.S. a 
Black 17 (81%) 4 (19%)   
Indian 2 (33.3%) 4 (66.7%)   
Size of Tumour   N.S. N.S. 
< 5 cm 11 (73.3%) 4 (26.7%)   
≥5 cm 8 (72.7%) 3 (27.3%)   
unavailable 1    
Histological type   N.S. N.S. 
Moderately differentiated 17 (68%) 8 (32%)   
Poorly differentiated 2 (100%) 0   
Depth of Invasion (pT)   N.S. N.S. 
Muscularis propria (pT2 1 (100%) ) 0   
Adventitia (pT3 18 (72%) ) 7 (28%)   
Adjacent structures (pT4 0 ) 1 (100%)   
Lymphatic node 
involvement 
  N.S. N.S 
(-) 8 (66.7%) 4 (33.3%)   
(+) 7 (77.8%) 2 (22.2%)   
Unavailable 4 (66.7%) 2 (33.3%)   
Myenteric plexus invasion   N.S. N.S 
(-) 1 (100%) 0   
(+) 18 (69.2%) 8 (30.8%)   
Perineurial invasion   N.S.  
(-) 3 (100%) 0   
(+) 16 (66.7%) 8 (33.3%)   
Lymphatic vessel invasion   N.S. N.S. 
(-) 3 (50%) 3 (50%)   
(+) 16 (76.2%) 5 (23.8%)   
Mitotic rate (no/10 HPF)   N.S. N.S. 
≤ 50 17 (73.9%) 6 (26.1%)   
>50 2 (50%) 2 (50%)   
Necrosis   N.S. N.S. 
Mild (0-33%) 17 (73.9%) 6 (26.1%)   
Moderate (34-66%) 2 (50%) 2 (50%)   
Anaplasia   N.S. N.S. 
(-) 3 (100%) 0   
(+) 16 (66.7%) 8 (33.3%)   
a Fisher’s exact test (2-sided), b Pearson chi-square test (2-sided) 
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3.8.2 Correlation between VEGF expression using SYBR Green I and clinicopathological 
factors 
The trends in VEGF expression as determined using the SYBR Green I system, in relation to 
clinicopathological features, are represented in Table 3.7. In group A, VEGF expression values 
showed a significant correlation with depth of invasion of tumour (p = 0.046). Most of the 
moderately invasive tumours showed upregulation of VEGF. In group B (percentages not 
shown), VEGF gene expression was not associated with any clinicopathological factors. 
Patients who were older than 50 years of age, or Black and male predominantly expressed 
VEGF upregulation.  Tumours that had invaded the adventitia mostly expressed VEGF 
upregulation. Most patients with moderately differentiated tumours showed VEGF 
upregulation.  Tumours less than 5 cm in size, positive for myenteric plexus invasion, 
perineurial invasion and lymphatic vessel invasion all showed VEGF upregulation.  Tumours 
that displayed anaplasia, a mitotic rate of 50 or less than 50 as well as mild and moderate 
necrosis expressed VEGF upregulation. None of the differences in up and down regulation of 
the VEGF gene within individual clinicopathological categories were however statistically 
significant (Table 3.7). 
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Table 3.7. Correlation between clinicopathologic variables and expression status of the VEGF 
gene (SYBR Green I system). 
 Group A    
(n = 27) 
  Group B      
(n = 19) 
Factors VEGF↑ VEGF↓ P P 
Age   N.S.  N.S.  
≤50  3 (50%) 3 (50%)   
>50 17 (81%) 4 (19%)   
Gender   N.S.  N.S.  
Male 8 (80%) 2 (20%)   
Female 12 (70.6%) 5 (29.4%)   
Race   N.S.  N.S. 
Black 16 (76.2%) 5 (23.8%)   
Indian 4 (66.7%) 2 (33.3%)   
Size of Tumour   N.S.  N.S.  
< 5 cm 13 (86.7%) 2 (13.3%)   
≥5 cm 7 (63.6%) 4 (36.4%)   
unavailable 1    
Histological type   N.S.  N.S.  
Moderately differentiated 18 (72%) 7 (28%)   
Poorly differentiated 2 (100%) 0   
Depth of Invasion (pT)   S (0.046) N.S. b 
Muscularis propria (pT2 0 ) 1 (100%)   
Adventitia (pT3 20 (80%) ) 5 (20%)   
Adjacent structures (pT4 0 ) 1 (100%)   
Lymphatic node 
involvement 
  N.S.  N.S.  
(-) 11 (91.7%) 1 (8.3%)   
(+) 5 (55.6%) 4 (44.4%)   
Unavailable 4 (66.7%) 2 (33.3%)   
Myenteric plexus invasion   N.S.  N.S.  
(-) 1 (100%) 0   
(+) 19 (73.1%) 7 (26.9%)   
Perineurial invasion   N.S.  N.S. 
(-) 2 (66.7%) 1 (33.3%)   
(+) 18 (75%) 6 (25%)   
Lymphatic Vessel invasion   N.S.  N.S.  
(-) 4 (66.7%) 2 (33.3%)   
(+) 16 (76.2%) 5 (23.8%)   
Mitotic rate (no/10 HPF)   N.S.  N.S.  
≤ 50 18 (78.3%) 5 (21.7%)   
>50 2 (50%) 2 (50%)   
Necrosis   N.S.  N.S. 
Mild (0-33%) 16 (69.6%) 7 (30.4%)   
Moderate (34-66%) 4 (100%) 0   
Anaplasia   N.S.  N.S.  
(-) 2 (66.7%) 1 (33.3%)   
(+) 18 (75%) 6 (25%)   
a Fishers exact test (2-sided), b Pearson chi-square test (2-sided) 
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3.8.3 Correlation between HER1 expression using UPL and clinicopathological factors 
Table 3.8 below shows the trends of HER1 expression in relation to clinicopathologic factors. 
Upregulation of the HER1 gene was not significantly associated with any clinicopathological 
factors. In all pathological categories, the majority of tumours showed HER1 upregulation.  
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Table 3.8. Correlation between clinicopathologic variables and expression status of the HER1 
gene. 
 Group A    
(n = 27) 
  Group B      
(n = 19) 
Factors HER1↑ HER1↓ P P 
Age   N.S.  N.S.  
≤50  5 (83.3%) 1 (16.7%)   
>50 17 (81%) 4 (19%)   
Gender   N.S.  N.S.  
Male 9 (90%) 1 (10%)   
Female 13 (76.5%) 4 (23.5%)   
Race   N.S.  N.S.  
Black 17 (81%) 4 (19%)   
Indian 5 (83.3%) 1 (16.7%)   
Size of Tumour   N.S.  N.S.  
< 5 cm 13 (86.7%) 2 (13.3%)   
≥5 cm 9 (81.8%) 2 (18.2%)   
unavailable 1    
Histological type   N.S.  N.S.  
Moderately differentiated 20 (80%) 5 (20%)   
Poorly differentiated 2 (100%) 0   
Depth of Invasion (pT)   N.S.  N.S. 
Muscularis propria (pT2 1 (100%) ) 0   
Adventitia (pT3 20 (80%) ) 5 (20%)   
Adjacent structures (pT4 1 (100%) ) 0   
Lymphatic node 
involvement 
  N.S.  N.S.  
(-) 10 (83.3%) 2 (16.7%)   
(+) 7 (77.8%) 2 (22.2%)   
Unavailable 5 (83.3%) 1 (16.7%)   
Myenteric plexus invasion   N.S.  N.S.  
(-) 1 (100%) 0   
(+) 21 (80.8%) 5 (19.2%)   
Perineurial invasion   N.S.  N.S.  
(-) 3 (100%) 0   
(+) 19 (79.2%) 5 (20.8%)   
Lymphatic Vessel invasion   N.S.  N.S.  
(-) 5 (83.3%) 1 (16.7%)   
(+) 17 (81%) 4 (19%)   
Mitotic rate (no/10 HPF)   N.S.  N.S.  
≤ 50 19 (82.6%) 4 (17.4%)   
>50 3 (75%) 1 (25%)   
Necrosis   N.S.  N.S.  
Mild (0-33%) 19 (82.6%) 4 (17.4%)   
Moderate (34-66%) 3 (75%) 1 (25%)   
Anaplasia   N.S.  N.S.  
(-) 3 0   
(+) 19 (79.2%) 5 (20.8%)   
a Fisher’s exact test (2-sided), b Pearson chi-square test (2-sided) 
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3.8.4 Correlation between HER2 expression using UPL and clinicopathological factors 
Table 3.9 below shows the trends in HER2 expression in terms of clinical and pathological 
features. In group A, HER2 upregulation was significantly associated with Black individuals 
whereas significantly more Indian patients displayed HER2 down regulation (p = 0.015). This 
trend was seen in group B (percentages not shown), but was not statistically significant. 
Upregulation of HER2 was predominant in most categories and especially in patients who 
were less than 50 years of age, in males more than females and in tumours that were less than 
or equal to 5cm. In group B, most tumours with mild necrosis and a mitotic rate of ≤ 50 
displayed HER2 upregulation whereas tumours with moderate necrosis and a mitotic rate of 
above 50 showed HER2 downregulation.  
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Table 3.9. Correlation between clinicopathologic variables and expression status of the HER2 
gene. 
 Group A    
(n = 27) 
  Group B      
(n = 19) 
Factors HER2↑ HER2↓ P P 
Age   N.S.  N.S.  
≤50  5 (83.3%) 1 (16.7%)   
>50 12 (57.1%) 9 (42.9%)   
Gender   N.S.  N.S.  
Male 8 (80%) 2 (20%)   
Female 9 (52.9%) 8 (47.1%)   
Race   S (0.015) N.S. a 
Black 16 (76.2%) 5 (23.8%)   
Indian 1 (16.7%) 5 (83.3%)   
Size of Tumour   N.S.  N.S.  
< 5 cm 11 (73.3%) 4 (26.7%)   
≥5 cm 6 (54.5%) 5 (45.5%)   
unavailable 1    
Histological type   N.S.  N.S.  
Moderately differentiated 15 (60%) 10 (40%)   
Poorly differentiated 2 (100%) 0   
Depth of Invasion (pT)   N.S. N.S.  
Muscularis propria (pT2 1 (100%) ) 0   
Adventitia (pT3 16 (64%) ) 9 (36%)   
Adjacent structures (pT4 0 ) 1 (100%)   
Lymphatic node 
involvement 
  N.S.  N.S.  
(-) 8 (66.7%) 4 (33.3%)   
(+) 5 (55.6%) 4 (44.4%)   
Unavailable 4 (66.7%) 2 (33.3%)   
Myenteric plexus invasion   N.S.  N.S.  
(-) 1 (100%) 0   
(+) 16 (61.5%) 10 (38.5%)   
Perineurial invasion   N.S.  N.S.  
(-) 2 (66.7%) 1 (33.3%)   
(+) 15 (62.5%) 9 (37.5%)   
Lymphatic vessel invasion   N.S.  N.S  
(-) 4 (66.7%) 2 (33.3%)   
(+) 13 (61.9%) 8 (38.1%)   
Mitotic rate (no/10 HPF)   N.S.  N.S.  
≤ 50 16 (69.6%) 7 (30.4%)   
>50 1 (25%) 3 (75%)   
Necrosis   N.S.  N.S.  
Mild (0-33%) 15 (65.2%) 8 (34.8%)   
Moderate (34-66%) 2 (50%) 3 (50%)   
Anaplasia   N.S.  N.S.  
(-) 3 (100%) 0   
(+) 14 (58.3%) 10 (41.7%)   
a Fisher’s exact test (2-sided), b Pearson chi-square test (2-sided) 
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3.8.5 Correlation between MMP2 expression using UPL and clinicopathological factors 
The trends of MMP2 gene expression in terms of clinicopathological features are shown in 
Table 3.10. The only characteristic to show any significant relationship with MMP2 
expression was lymphatic node metastasis (p = 0.030) in group A. Patients with lymphatic 
node metastasis mainly showed MMP2 downregulation and patients without lymphatic node 
metastasis showed MMP2 upregulation. The MMP2 gene expression in group B (percentages 
not shown) was not associated with any clinicopathologic factors but showed similar trends 
except with respect to ethnicity. In group A, most Indian male individuals presented MMP2 
upregulation whereas in group B most Black male individuals showed MMP2 upregulation. In 




Table 3.10. Correlation between clinicopathologic variables and expression status of the 
MMP2 gene. 
 Group A    
(n = 27) 
  Group B     
(n = 19) 
Factors MMP2↑ MMP2↓ P P 
Age   N.S.  N.S.  
≤50  2 (33.3%) 4 (66.7%)   
>50 15 (71.4%) 6 (28.6%)   
Gender   N.S.  N.S.  
 Male 7 (70%) 3 (30%)   
 Female 10 (58.8%) 7 (41.2%)   
Race   N.S.  N.S.  
 Black 13 (61.9%) 8 (38.1%)   
 Indian 4 (66.7%) 2 (33.3%)   
Size of Tumour   N.S.  N.S.  
< 5 cm 11 (73.3%) 4 (26.7%)   
≥5 cm 6 (54.5%) 5 (45.5%)   
unavailable 1    
Histological type   N.S.  N.S.  
Moderately differentiated 15 (60%) 10 (40%)   
Poorly differentiated 2 (100%) 0   
Depth of Invasion (pT)   N.S.  N.S.  
Muscularis propria (pT2 1 (100%) ) 0   
Adventitia (pT3 15 (60%) ) 10 (40%)   
Adjacent structures (pT4 1 (100%) ) 0   
Lymphatic node 
involvement 
  S (0.030) N.S.  b 
(-) 8 (66.7%) 4 (33.3%)   
(+) 3 (33.3%) 6 (66.7%)   
Unavailable 6  0   
Myenteric plexus invasion   N.S.  N.S. 
(-) 1 (100%) 0   
(+) 16 (61.5%) 10 (38.5%)   
Perineurial invasion   N.S.  N.S.  
(-) 1 (33.3%) 2 (66.7%)   
(+) 16 (66.7%) 8 (33.3%)   
Lymphatic Vessel invasion   N.S.  N.S.  
(-) 4 (66.7%) 2 (33.3%)   
(+) 13 (61.9%) 8 (38.1%)   
Mitotic rate (no/10 HPF)   N.S.  N.S.  
≤ 50 16 (69.6%) 7 (30.4%)   
>50 1 (25%) 3 (75%)   
Necrosis   N.S.  N.S.  
Mild (0-33%) 15 (65.2%) 8 (34.85%)   
Moderate (34-66%) 2 (50%) 2 (50%)   
Anaplasia   N.S.  N.S.  
(-) 3 (100%) 0   
(+) 14 (58.3%) 10 (41.7%)   
a Fisher’s exact test (2-sided), b Pearson chi-square test (2-sided) 
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3.9 Comparison of the correlation of VEGF expression with clinicopathological factors 
using the UPL and SYBR Green I systems  
 
The McNemar Chi–squared test showed that the correlation of clinicopathologic factors with 
VEGF gene expression was the same irrespective of which system (UPL or SYBR Green I) 
was used to detect gene expression (p = 1.00). 
 
3.10 Evaluation of correlations between all clinicopathological factors 
As shown in Table 3.11, lymphatic node metastasis was associated with tumour mitotic rate in 
both groups A and B, but was statistically significant only in group B. The depth of tumour 
invasion was the only clinicopathological feature shown to be significantly associated with 
anaplasia in group A. Large tumours were significantly associated with mitotic rate and 
necrosis in group B. Gender was significantly associated with race and perineurial invasion in 
group A. 
 
Table 3.11. Correlation between clinicopathologic factors. 
 
 P value (Group A) P value (Group B) 
 





Depth of invasion vs Anaplasia N.S. S (0.043)
Tumour size vs Necrosis 
a 
S. (0.015) N.S. b 
Tumour size vs Mitotic rate  N.S. S (0.043)
Gender vs Perineurial invasion 
 a 
S (0.041) N.S. a 
Gender vs Race S (0.057) N.S.  a 
a Fishers exact test (2-sided), b 
 
Pearson chi-square test (2-sided) 
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3.11 Gene expression inter-relationships 
 
The relationship between the expressions of each of the 4 genes studied was examined by 
carrying out correlation and linear regression analyses using the mRNA (Tumour/Normal) 
transcript levels of each gene relative to the other genes, as shown in Table 3.12. A Pearson’s 
correlation (2-tailed) was calculated using the statistical package program SPSS. The linear 
correlation coefficient values shown in Table 3.12, is the measure of the strength and the 
direction of a linear relationship between the genes. 
 
Table 3.12. Gene expression correlation coefficients between the four genes in Groups A and 
B.  
 VEGF HER1 HER2 MMP2 





















____ -0.026 (A) 
 
-0.042 (B) 












Note: * Correlation is significant at p = 0.01  
Positive slope: expression of the two genes tends to increase or decrease together 





Expression of the VEGF expression was significantly associated with expression of both the 
HER1 and MMP2 genes in a positive manner, while HER1 expression was similarly associated 
with MMP2 expression. Expression of the HER2 gene was not associated with expression of 
any of the other genes studied. These relationships were observed in both groups A and B. The 
correlation coefficients were however all higher in group B than in group A suggesting that 
the removal of discordant samples from group A strengthened the correlation between gene 
expression. 
 
The coefficient of determination (R squared linear) values were calculated for the correlation 
analysis between gene expressions, as seen in the figures below. These values represent the 
proportion of the variation of one gene that is predictable from the other gene. The fit of the 
regression line to the gene expression data shows how well the amount of variation between 
the genes can be explained by the linear relationship. 
 
VEGF expression was associated with MMP2 expression by a factor of 21.6% (R2 = 0.216) in 
group A and 79.8% (R2 
 
= 0.798) in group B (Figure 3.20). The increase in the correlation 
observed between the expression of these two genes in group B was most likely due to the 
removal of discordant samples from group A. The discordant samples in group A presented 
outliers and did not fall into the normal trends of distribution of the gene expression values, as 





Figure 3.20. Correlation between the mRNA levels of VEGF/GAPDH and MMP2/GAPDH in Groups 
A and B. 
 
HER1 expression was associated with VEGF expression by a factor of 86.3% (R2 = 0.863) in 






Figure 3.21. Correlation between the mRNA levels of HER1/GAPDH and VEGF/GAPDH in Groups 
A and B. 
 
HER1 expression was associated with MMP2 expression by a factor of 24.9% (R2 = 0.249) in 
group A and 88.8% (R2 = 0.888) in group B (Figure 3.22).  
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Figure 3.22. Correlation between the mRNA levels of HER1/GAPDH and MMP2/GAPDH in Groups 
A and B. 
 
The increase in correlation between HER1 and MMP2 gene expression in group B was most 
likely due to the removal of discordant samples from group A. The discordant samples in 
group A presented outliers and did not fall into the normal trends of distribution of the gene 
expression values. This distribution pattern was also observed between the expression of 
VEGF and MMP2 genes (Figure 3.20). 
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Chapter 4: Discussion 
 
4.1 Introduction 
Squamous cell carcinoma of the oesophagus is one of the most common malignancies 
worldwide with marked variations in geographical and ethnic distribution (Holmes and 
Vaughan, 2007). In South Africa, OSCC was reported to be the most commonly occurring 
cancer in Black individuals for the period between 1996 and 2000 (www.mrc.ac.za; Sammon, 
2007). Clearly an understanding of the pathogenesis of OSCC, including underlying molecular 
changes, is required to develop and implement appropriate diagnostic and therapeutic 
interventions.  
 
The current study was therefore carried out to evaluate whether changes in gene expression 
contribute to tumourigenesis in squamous cells of the oesophagus by assessing the relative 
gene expression of four well-described oesophageal cancer related genes, namely VEGF, 
HER1, HER2 and MMP2, in a cohort of oesophageal cancer patients from the KZN region. 
Real time PCR technology was used to assess gene expression, as it is a reliable and rapid 
means of detecting and quantifying gene copy numbers. Additionally, this study aimed to 
evaluate a novel real time PCR probe detection system, namely the UPL system, by comparing 
it to the existing SYBR Green I dye fluorescence system. Relative gene expression was 
deduced by two different quantification methods, namely the standard curve method and the 





Relationships between gene expression data and patient/tumour characteristics were also 
assessed, as well as relationships between clinicopathological factors, and between the 
expressions of the various genes. Finally, the study critiqued the impact of specimen sampling 
on the outcome of the investigation. 
 
4.2 Comparison between the SYBR Green I method and UPL detection systems in real 
time PCR  
Real time PCR technology has been used widely in both diagnostics and gene expression 
analysis. Several detection systems for use with real time PCR are available, ranging from 
simple intercalating dye systems to newer probe based systems (Bonetta, 2005). This study 
assessed the detection abilities of SYBR Green I, a standard fluorescent dye sytem and UPL, a 
hydrolysis probe based system.  
 
Overall the differences between the two systems based on VEGF gene expression were found 
to be statistically insignificant. There was however, a significant difference between the two 
detection systems when comparing the VEGF expression values in normal and tumour 
oesophageal tissue (Table 3.4). Although the tests performed in this study concluded that both 
systems were similar in their detection abilities, it was found that the SYBR Green I system 
showed a constant pattern of overestimation of gene expression when compared to the UPL 
system. The SYBR Green I system overestimated the frequency of up and down regulation by 
7% in group A and 14% in group B (Table 3.3). It also overestimated fold change values 
calculated using the Pfaffl model, by factors of 2 and 3, in groups A and B, respectively 
(Figure 3.14).  
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The overestimation of gene expression may be due to the inherent properties of the 
intercalating dye system which can cause false positive values. With SYBR Green I assays, 
the intercalating dye labels all PCR amplified double stranded DNA, including non specific 
products and primer dimers. In contrast, the UPL detection system is probe based and relies on 
the sequence specific detection of a desired PCR product by labeled probes.  
 
The SYBR Green I system also reported lower CP values for normal and tumour oesophageal 
tissue (Appendix H) compared with the UPL system. This resulted in the detection of an 
increased concentration of PCR product. Similar results were reported in several UPL 
functionality studies (Horst and Peterhänsel, 2007; Mauritzen et al., 2005). Furthermore, the 
differential VEGF gene expression between normal and tumour oesophageal tissue as detected 
with the SYBR Green I system was significantly different in groups A and B, but only of 
borderline significance when detected with the UPL system. This statistical significance seen 
with the SYBR Green I system may be due to the overestimation in gene expression values of 
normal and tumour oesophageal tissue, whereas the more specific UPL system detected a 
smaller difference between the tissue types. These observations are in agreement with other 
studies comparing SYBR Green I and UPL/ probe based assays, in which a more reliable 
performance was observed with the UPL/ probe systems (Horst and Peterhänsel, 2007; Leucht 
and Bally-Cuif, 2007; Newby et al, 2003).  
 
In a comparison of the laboratory usage of the two detection systems, the UPL system proved 
to be more user friendly and cost effective.  Primers and probes designed by the probe finder 
software required very little user input and worked efficiently.  
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In addition, the UPL system can be used without any optimisation of PCR conditions, 
although for the purposes of this study, amplicons created using the SYBR Green I system 
were used to construct standard curves for the UPL system, and therefore optimisation was 
required. In contrast, the SYBR Green I system was time consuming as optimisation of PCR 
conditions was required for each gene to eliminate non specific amplification products such as 
primer dimers. This also resulted in increased costs. An infrequent limitation observed with 
the UPL system was probe degeneration at later cycles (cycle 36 onwards) when a sharp 
increase in the fluorescence of all samples, including the negative control was observed. 
Despite this, overall, the UPL system demonstrated more stability at later cycles than the 




Real time PCR is a versatile technology that allows for the accurate measurement of gene 
expression. It is relatively simple to perform and provides reliable results. In this study, the 
evaluation of gene expression using real time PCR demonstrated that the UPL detection 
system simplified the real time PCR assays. While the results obtained were similar to those 








4.3 Comparison of real time PCR quantification methods 
The choice of a reliable quantification method for use in real time PCR is critical for the 
accurate determination of gene expression. The real time PCR quantification methods used in 
this study, namely the standard curve method and the Pfaffl model, showed similar results in 
their evaluation. In a comparison of the gene expression fold change values between the two 
different methods of quantification, the fold change factors ranged from 0.2 to 1.9. The fold 
change values generated by the Pfaffl model were generally higher than those obtained using 
the standard curve model. This may be attributed to the efficiency correction used in the Pfaffl 
model and suggests that the standard curve model underestimated the degree of gene 
expression as a result of the underestimation of the actual efficiency of reactions. Relative 
gene expression with the Pfaffl model is reported to be more accurate since it determines 
whether there is a significant difference between samples and controls, while taking into 
account issues such as reaction efficiency and reference gene normalisation by using 
randomisation techniques (Pfaffl, 2002).  
 
Studies have shown that small differences in the PCR efficiency can result in more than a ten 
fold variation in the calculation of sample amount. Efficiency correction is therefore essential 
for gene expression investigations using real time PCR (Roche Diagnostics, 2001). The 
calculation of gene expression with the Pfaffl model using the incorporated REST database 
was simple and efficient to use since statistical tests, normalisation with housekeeping gene 
and the efficiency of reactions were all incorporated into a single spreadsheet. Efficiency 
curves were also easier to create than standard curves, since the need for the creation of 




The Pfaffl model with incorporated REST software provides a simple and efficient 
mathematical model for data analysis. In contrast to complex, time consuming quantification 
models based on standard curves, the Pfaffl model produces rapid and reproducible relative 
gene expression quantification. 
 
4.4 Relative expressions of the VEGF, HER1, HER2 and MMP2 genes 
Individually almost all oesophageal tumours in this study demonstrated the upregulation of the 
VEGF, HER1, HER2 and MMP2 genes irrespective of the detection system used, or the 
method of analysis. All genes were significantly upregulated in both groups A and B, with the 
exception of HER1 in group B, when using the UPL system with the Pfaffl model (Figure 
3.14). With use of the standard curve method, only VEGF expression using SYBR Green I and 
HER1 expression using UPL, demonstrated statistically significant upregulation (Figure 3.17, 
3.18). In terms of the amount of upregulation, expression of the VEGF was found to be 
upregulated by the highest factor using the standard curve method, whereas the HER2 gene 
displayed the highest degree of upregulation with the Pfaffl model. The MMP2 gene 
demonstrated the least amount of upregulation as calculated by both models. With respect to 
the frequency of upregulation in the study population, overexpression of HER1 was more 
common in individual patients compared to VEGF. All other genes demonstrated high 





The findings of this study suggest that VEGF, HER1, HER2 and MMP2 are related to the 
growth and metastases of oesophageal carcinoma due to their increased expression in tumours.  
Oesophageal tumours require increased proliferation, sustained angiogenesis and the ability to 
invade through the ECM, in order to expand locally and spread to distant sites. The increased 
expression of HER1, HER2, VEGF and MMP2 support these properties of cancer cells. Most 
patients in this study have advanced OSCC (Table 3.5), suggesting that the overexpression of 
these genes is important for the progression of the disease. The results of this study are 
consistent with reports on other studies in which overexpression of the VEGF, HER1, HER2 
and MMP2 genes have been associated with advanced OSCC (Martinez et al, 2003).  
 
This the first study however, to report on the gene expression of VEGF, HER1, HER2 and 
MMP2 in oesophageal tumours in South African individuals. Since OSCC demonstrates a 
marked variation with regard to ethnicity, there is an obvious need to conduct studies of this 
nature in different ethnic groups and populations. 
 
Conclusion and future perspectives 
The genes for VEGF, HER1, HER2 and MMP2 are widely reported to be influential for the 
growth and development of oesophageal tumours (Martinez et al, 2003). This study establishes 
the overexpression of these genes in oesophageal tumours of a South African population. 
Further studies investigating the exact roles and mechanisms of these genes in the progression 
of OSCC need to be conducted with a particular focus on high incidence populations, such as 




4.5 Correlation of gene inter-relationships  
In this study, regression analyses of mRNA transcript levels revealed a strong correlation 
between the VEGF, HER1 and MMP2 genes (Table 3.12), suggesting a possible association 
between the transcription of these genes. It has been postulated that the VEGF and HER1 
pathways are related with respect to tumour induced angiogenesis (Tabernero, 2007). Several 
studies have reported that tumour associated endothelial cells activate HER1, which in turn 
induces VEGF expression in cell culture models (Ellis, 2004; Kim, et al., 2003; Perrotte, et al., 
1999). It has also been suggested that the HER1 pathway modulates angiogenesis in tumours 
by upregulating VEGF and/or other components of the angiogenic cascade, including the 
MMPs (Perrotte, et al., 1999). Figure 4.1 below, modified from Tabernero, (2007), illustrates 
the hypothesis governing the initiation of the angiogenic process, following the release of 
VEGF by tumour cells initiates the angiogenic process.  
 
Figure 4.1 Features that promote tumour induced angiogenesis. 
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Expression of VEGF is driven by many factors including the expression of oncogenes such as 
HER1, HER2 and ras, and other factors, such as hypoxia. The binding of VEGF to its receptor 
results in the activation of intracellular signalling pathways that are involved in endothelial 
cell proliferation and migration (Tabernero, 2007). Endothelial cell activation results in the 
secretion of matrix metalloproteinases, urokinase plasminogen activator and receptor which 
degrade the ECM, and allows proliferating cells to migrate towards the tumour cells. 
Pathologic angiogenesis is essential for the tumour as it provides means for its growth and 
dissemination (metastases). Other studies have reported that the blockage of HER1 by 
inhibitors resulted in the down regulation of pro-angiogenic mediators, including VEGF (Ellis, 
2004). This allowed continued tumour angiogenesis and growth, but at a much reduced level, 
suggesting that inhibition of HER1 alone cannot completely block VEGF production because 
its expression is regulated by many other factors.  Thus, the observed gene inter-relationship 
correlations demonstrated in this study supports previous reports linking VEGF, HER1 and 
MMP2 gene expression. 
 
Conclusion and future perspectives 
Associations between VEGF, HER1 and MMP2 are clearly evident in this study although 
further confirmation is essential. Such studies may provide clues to molecular events related to 
the carcinogenesis of OSCC and suggest possible therapeutic targets. The overexpression of 
VEGF, EGF and their receptors (HER1, HER2) and MMPs observed in many human 
neoplasms supports the postulate discussed above. The use of inhibitory agents to several of 
these gene products has produced promising results and a multi-targeted therapeutic approach 
to cancer aimed at targeting different molecular agents has proved to be more successful than 
targeting a single agent (Tabernero, 2007). 
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4.6 Histological assessment of tissue sampling method 
The retrospective assessment of sampling methods is useful to verify that the tissue used was 
accurately classified. This contributes to ensuring that the results obtained are reliable and 
reproducible. Retrospective analysis provides the potential for improvement in the 
methodological approach in future studies. It is essential that the starting material used for any 
study is of satisfactory quality and is obtained using standardised and ethically sound 
laboratory practices.  
 
As was clear from the retrospective histological assessment of the samples used in this study, 
the quality of some of the tissue provided was poor with an insufficient amount of squamous 
cells present for reliable investigation. Approximately 11% of ‘tumour’ samples had a low 
percentage of tumour cells while 26% of ‘normal’ samples contained tumour cells within the 
sample. The quantitative gene expression calculated from these samples cannot therefore be an 
accurate representation of expression status. One possible reason for these discrepancies could 
be that the bulk of the normal or tumour tissue in these samples had been excised previously 
for other purposes. In order not to confound the study results, data analyses were subsequently 
performed on two groups, with (Group A) and without (Group B) the discordantly classified 
samples.  
 
Furthermore, in gene expression studies it is important to ensure that the ‘normal’ tissue is free 
of dysplastic areas because these areas are known to be associated with inflammation (Lu et al, 
2006). Inflammation is defined as the local physiological response to tissue injury 
(Underwood, 2000) and results in the stimulation of several genes, including VEGF, HER1, 
HER2 and MMPs.  
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Several studies have reported the overexpression of the MMP2 gene in areas of cellular 
dysplasia (Coussens and Werb, 2002; Samantaray et al., 2004; Underwood, 2000). Clearly the 
estimation of gene expression levels from ambiguous samples would be inaccurate. In this 
study, dysplasias were evident in several ‘normal’ oesophageal samples (Appendix I: Samples 
1, 11 and 45), Appendix J: Figure J.12). These inaccurately classified samples were excluded 
from group B.  
 
The relative gene expression data generated with the standard curve model in group A 
(comprising of all samples) showed many outlying results for both normal and tumour 
oesophageal tissue (Figures 3.17, 3.18). Following the removal of the discordant samples from 
group B, these outliers disappeared and the gene expression data assumed a normal pattern of 
distribution. Similar observations were noted for gene association correlations using linear 
regression (Table 3.12 and Figures 3.20, 3.21, 3.22). With respect to the histopathological 
correlation with gene expression, several differences were observed between groups A and B. 
These differences could however also have been attributed to the smaller sample size in group 
B which diminished the statistical power of the test. 
 
The assignation of normal and tumour oesophageal tissue based on visual inspection of the 
surgical specimen alone, can clearly result in misclassification, as observed in this study. Fresh 
or frozen normal, dysplastic and tumour tissue that is classified by a pathologist is frequently 
favoured in gene expression studies, as the yield and quality of RNA is good, although limited 
availability of fresh tissue could be restrictive.  
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Studies have reported that a good quality of tissue sample is ensured when using formalin-
fixed paraffin-embedded (FFPE) methods since it is possible to choose adequately 
representative regions of sample type (Chen et al., 2007; Cronin et al., 2004; Gloghini et al., 
2004; Godfrey et al., 2000). Although the process of formalin fixation may contribute to RNA 
degradation, recent technical developments now allow the isolation of high quality RNA from 
FFPE samples for use in real time PCR and gene array experiments (Chen et al., 2007; Cronin 
et al., 2004; Gloghini et al., 2004; Godfrey et al., 2000). 
 
Conclusion and future perspectives 
The retrospective assessment of experimental sampling methods carried out in this study 
highlights the important role of optimal sampling and laboratory practice in research. 
Additionally, it also demonstrates the need for effective team work, as well as discipline 
specific expertise and accountability in inter-and multidisciplinary research. Based on the 
observations made in this study, it is recommended that gene expression studies should utilise 
formalin-fixed paraffin-embedded (FFPE) tissues as they are readily available, and are 
accurately and comprehensively classified. 
 
4.7 Correlation of gene expression to clinicopathological profile  
The present study cohort comprised mostly Black African patients, reflecting the local 
demographic public sector hospital admissions. Cancer of the oesophagus is characterised by a 
2:1 male: female prevalence (Blot, 1994), but in this study cohort there were more females 
than males. This preponderance of females is most likely related to the small sample 
population. The inclusion of patients in early and intermediate stage of OSCC is desirable to 
allow the comparison of gene expression with disease progression.  
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In this study however, most patients presented with an advanced disease stage in which 
tumours had already spread to the adventitia at the time of diagnosis. It is not always possible 
to include patients with different disease stages in short term studies that utilise frozen sample 
tissue for analysis. Analysis of gene expression in relation to clinical or phenotypic variations 
may indicate biologically meaningful changes at a transcriptional level. Such studies such may 
provide evidence for associations between upregulated genes and carcinogenesis, or between 
gene expression and clinical factors. 
 
In this study, all male patients displayed significant overexpression of VEGF gene (p = 0.012 
(A), p = 0.044 (B)).  In group A, all Black patients displayed significant overexpression of 
VEGF gene (p = 0.044). This suggests gender and race may have an influence on VEGF 
expression. The upregulation of HER2 was also significantly associated with race in group A 
(p = 0.015), at least, suggesting a possible association between race and HER2 expression in 
OSCC. Furthermore, gender was significantly associated with race when evaluating prognostic 
factors (Table 3.11). Overexpression of VEGF in this study, as evaluated using the SYBR 
Green I system, in group A, was also significantly correlated with depth of tumour invasion. 
Most tumours that had invaded the adventitia displayed significant VEGF overexpression (p = 
0.046). As discussed previously in Chapter 1, VEGF is a key regulator of angiogenesis and 
provides the growing tumour with the necessary vascular development required for both local 
growth and distant metastasis (Ciardiello et al., 2006, Folkman, 2003). An association between 
increased VEGF protein expression in squamous cell carcinoma and an increased depth of 
tumour invasion, tumour stage, lymph node and distant metastases and a poorer survival has 
been reported (Vallböhmer and Lenz, 2006).  
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These findings suggest the possibility that the advanced oesophageal carcinomas investigated 
in this study employed similar angiogenic pathways for their local growth and spread.  
 
Other genes that are involved in the spread of tumours are MMPs, which are directly involved 
in tumour invasion by means of ECM degradation and the maintenance of the tumour 
microenvironment. Matrix Metalloproteinase 2 has been suggested to be involved in the early 
events of malignant transformation in several cancers, including oesophageal, cervical, oral 
and lung cancers (Samantaray et al., 2004). Increased MMP2 protein expression in OSCC has 
been associated with increased depth of tumour invasion, tumour stage, vascular/lymphatic 
vessel invasion and poorer survival (Vallböhmer and Lenz, 2006). However, several other 
studies have reported no significant association between MMP2 protein expression and 
lymphatic node invasion (Koyama et al, 2000; Samantaray et al., 2004).  
 
In this study, group A of oesophageal tumours demonstrated a significant association of 
MMP2 gene overexpression in patients without lymphatic node invasion (p= 0.030). This 
could be explained by the reported involvement of MMPs in the critical events of tumour 
evolution at earlier stages, such as tumour promotion, modulation of the growth of the primary 
tumour and angiogenesis (Samantaray et al., 2004). The overall absence of a correlation of 
MMP2 overexpression with tumour invasion and other signs of advanced disease in this and 
other studies, suggests the role of MMP2 in early tumour development.  
 
Growth factor receptors such as HER1 and HER2 are also directly involved in neoplastic 
transformation and involved in the regulation of cellular proliferation and differentiation 
(Ciardiello et al, 2006).  
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Reports of increased HER1 and HER2 protein expression have been linked to an increased 
local recurrence, depth of tumour invasion, lymph node metastasis and a poorer survival in 
OSCC (Dreilich et al., 2006; Vallböhmer and Lenz, 2006). In this study however, no 
significant associations of HER1 and HER2 overexpression with clinicopathological factors 
were observed.  
 
Another factor that is essential for tumour growth is the rate of cell proliferation. The division 
of cells occurs by the process of mitosis, which is part of the cell cycle and defined by the 
appearance of cytologically detectable chromosomes (Čemerikić-Martinović et al, 1998) 
(Appendix J: Figure J.1). In group B of oesophageal tumours in this study, the mitotic rate of 
the tumour was significantly associated with the size of the tumour (p = 0.043), as well as 
lymph node metastasis (p = 0.044). This suggests that the mitotic index of a tumour may be 
linked in some manner to the rate of local tumour growth, as well as distant spread. Cancer 
cells frequently exhibit a higher mitotic index than the corresponding normal cell population, 
and higher frequencies of cellular proliferation have been reported to be associated with a poor 
prognosis (Underwood, 2000). In group B, larger tumours were significantly associated with 
an increased presence of necrosis (p = 0.043) (Appendix J: Figure J.3). Necrotic areas are 
capable of stimulating angiogenic factors that promote the growth and movement of 
endothelial cells, thus providing the tumour with vasculature (Ribatti and Vacca, 2008). A 
study by Ikpatt et al, (2002) in breast cancer patients also reported a correlation of necrosis 
with the size of the tumours and suggested that necrosis was associated with progressive and 
advanced disease. Thus the results from this study together with others, suggest that in 
oesophageal tumours, necrosis may be a means by which tumours increase vasculature for 
growth purposes.  
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Another factor that is reported to influence the growth of tumours is perinuerial invasion 
(PNI). This occurs when cancer cells invade the perineurium (Appendix J, Figure J.7) and is 
reported to be a crucial route for the local spread of gastric tumours associated with poor 
prognosis (Duraker et al, 2003). Perineurial invasion was reported to be closely related to local 
recurrence of OSCC in patients and was classified as an important prognostic factor for the 
disease (Tanaka et al., 1998). In this study, PNI was not associated with any clinicopathologic 
factors except for the female gender in group A (p = 0.041). This observation could however 
be due to the higher number of female participants in this study.  
 
The majority of oesophageal carcinomas in this study were moderately differentiated and it 
was observed that increased anaplasia was significantly associated with increased depth of 
tumour invasion in group A (p= 0.015). The degree of differentiation of tumours is clinically 
useful as it is associated with prognosis and may influence therapeutic choices (Underwood, 
2000). Poorly differentiated cells may be anaplastic and lack similarity to surrounding normal 
cells (Underwood, 2000). Poorly differentiated tumours are reported to have high mitotic rates 
indicating rapid and aggressive growth compared to well or moderately differentiated tumours 
(Underwood, 2000).  
 
The TNM status of oesophageal tumours in this study was not analysed in relation to gene 
expression data as information on the metastasic status of the tumour was unavailable or 
incomplete. The combination of the TNM classification and VEGF expression has been 
reported to be a possible means of devising therapy using angiogenesis inhibitors (Shih et al., 
2000). Gene expression data were however not correlated with patient survival in this study 
due to the unavailability of accurate patient survival statistics. 
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 Conclusion and future perspectives 
The overexpression of VEGF in this study was influenced by gender and race, as well as by an 
increased depth of tumour invasion. Overexpression of HER2 was influenced by race only, 
while overexpression of the MMP2 gene was related to patients who did not have lymphatic 
node metastasis. Clinically, large tumour size was associated with an increased mitotic rate 
and an elevated amount of necrosis. Anaplasia was frequently observed with an increased 
depth of tumour invasion and perineurial invasion was influenced by gender. Further scientific 
evidence confirming these correlations are essential, as are larger prospective studies to 
confirm the relationship between gene expression levels and prognosis.  
 
Studies such as the current one are useful in identifying new molecular and prognostic markers 
for OSCC. The prevention and early diagnosis of OSCC is as important as treatment of the 
disease. The pathophysiological and clinical aspects of tumours need to be studied in 
combination to gain perspective and insight into the multi-faceted nature of the disease. To 
successfully devise and perform such studies, strong interdisciplinary co-operation is required 





Appendix A: Reagents required for RNA extraction 
 
1. Diethyl pyrocarbonate water 
250µl Diethyl pyrocarbonate (DEPC) (0.001mmol/l) (Catalogue number: 150902, ICN 
Biochemicals Inc.) was added to 250ml of distilled water in a fume cupboard and 
incubated overnight at 37˚C. The solution was autoclaved twice before use. 
 
2. Ethanol (75%) 














Appendix B: Reagents required for gel electrophoresis 
 
1. Tris-Borate/EDTA (TBE) Buffer 
9.3g EDTA (31.8mmol/l), 55g Boric acid (889.5mmol/l) and 108g Tris base 
(891.8mmol/l) were dissolved in 1000ml of sterile water, filtered and then stored. 
 
2. Ethidium Bromide Dye 
100mg of Ethidium bromide (0.25mmol/l) was dissolved in 1ml of sterile water. The tube 
was covered with aluminium foil and stored at room temperature. 
 
3. Bromophenol Blue dye 
The solution consisted of 50% glycerol, 0.02% bromophenol blue and 0.02% xylene 
cyanol. 
 
4. 10x MOPS (3-[N-Morpholino] propanesulfonic acid) (Catalogue no. M-1254, (Sigma, 
Germany). 
41.9g of MOPs (200mmol/l), 4.1g of sodium acetate (50mmol/l) and 3.7g of EDTA 
(10mmol/l) were added to a one litre flask and the pH was adjusted to 7 using a ph meter. 







Appendix C: RNA isolation using TRIZOL method  
 
50-100mg of normal or tumour oesophageal tissue was thoroughly homogenised in 1ml Trizol 
reagent and passed through a 21 gauge needle to disrupt the cells. The homogenate was 
centrifuged at 12000 gravitational force (g) for 10 minutes at 4°C before 200µl of chloroform 
was added. This mixture was shaken vigorously for 30 seconds and incubated at room 
temperature for 5 minutes before centrifugation at 12000g for 15 minutes at 4°C. The 
supernatant which contained the total RNA was transferred to a clean 1.5ml eppendorf tube 
and mixed with equal volume of 60% ethanol for subsequent RNA purification (Perou et al., 
1999). 
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Appendix D: RNA purification using Aurum Total RNA mini kit 
 
700µl of 60% ethanol was added to the RNA, mixed and allowed to stand for 1 minute.  The 
elution solution was placed in a water bath at 70̊C. A RNA binding column was inserted into 
a 2ml capless tube containing the binding column. The lysate was transferred on to the 
column. The tube was centrifuged for 1 minute at room temperature and the filtrate was 
discarded. All centrifugations were carried out at 12000g. 700µl of low stringency wash 
solution was added to the RNA binding column, centrifuged for 1 minute and the filtrate 
discarded. 75µl of DNase dilution solution was added to 5µl of reconstituted DNAse. 1.80µl 
of this solution was added to the RNA binding column and incubated at room temperature for 
25 minutes. The column was then centrifuged for 30 seconds and the filtrate discarded. 700µl 
of high stringency wash solution was added to the column which was then centrifuged for 30 
seconds and the filtrate was discarded. 700µl of low stringency wash solution was added to the 
column and centrifuged for 30 seconds. The filtrate was discarded and the column was 
centrifuged for an additional minute. The RNA binding column was placed into a sterile 1.5 
ml capped tube and 80µl of 70˚C elution solution was placed on the membrane stack, allowed 
to incubate for 1 minute and then centrifuged for 2 minutes in order to elute out pure RNA 
(Biorad package insert). 
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Appendix E: Agarose gel electrophoresis protocol  
 
A 2% agarose gel was prepared by dissolving 1.4g agarose in 70ml TBE buffer (x1) 
(Appendix B) in a 200ml conical flask. The solution was heated in a microwave until all the 
agarose had dissolved. After cooling, 3.5µl of ethidium bromide was added (Appendix B). The 
gel was then poured into a casting tray with a comb in place, and allowed to set for 45 minutes 
at room temperature. The comb was then gently removed and the tray was submerged in an 
electrophoretic tank containing TBE buffer (x1). 5µl of RNA sample was added to 2µl of 
bromophenol blue loading dye and the mixture was loaded into wells. Electrophoresis was 
carried out at 90V for 1 hour at room temperature (Maniatis et al., 1989). The RNA was then 
visualised and photographed using the Chemidoc UV transilluminator (Biorad). 
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Appendix F: Denaturing gel electrophoresis  
 
All gel trays, combs and rigs were wiped clean with RNase Zap (Ambion, USA) and rinsed 
with DEPC treated water before use (Appendix A). A 1% (w/v) agarose gel was prepared by 
adding 0.5g agarose, 5ml MOPS (10 x) (Appendix B) and 37.5ml DEPC water to a 200ml 
Erlenmeyer flask. This mixture was heated in a microwave until the agarose had dissolved. 
After cooling, 3.5 ml formaldehyde (37%) (Appendix B) was added to the solution in a fume 
cupboard. The solution was poured into a casting tray and allowed to set for 30 minutes. The 
gel was then placed onto the gel rig and 200ml of MOPS (1x) (Appendix B) was gently 
poured in, ensuring that the gel was completely covered. The RNA samples were prepared by 
adding 5ug of total RNA to 2µl of loading buffer (5x), 1µl ethidium bromide (Appendix B) 
and 10µl water in eppendorf tubes. The RNA samples were spun briefly in a microcentrifuge. 
The samples were heated at 65̊C for 10 minutes then left to chill on ice for 2 minutes and 
spun in a microcentrifuge briefly. The samples were then loaded into the wells of the gel. 
Electrophoresis was carried out at 80V for 40 minutes at room temperature (University of 
Pretoria laboratory manual, 2006). The gel was visualised and photographed using the 
















































































Appendix G (ii): UPL primers and probes 
Probes and primers were designed by Roche Diagnostics using the UPL design software 
(www.probelibrary.com). 
 
Genes UPL probes number 
VEGF 9 (cat.No. 04685075001) 
MMP2 43 (cat. No. 04688031001) 
HER1 83 (cat.no. 04689062001) 
HER2 46 (cat. No. 04688066001) 










 Oligonucleotide primer sequence 
(5’-3’) 




Gene-VEGF     
Forward AGT GTG TGC CCA CTG AGG A 19 57.9 58.8 
Reverse GGT GAG GTT TGA TCC GCA TA 20 50.0 57.3 
Gene- MMP2     
Forward TTG GCA GTG CAA TAC CTG AA 20 45.0 55.3 
Reverse CTT CAG CAC AAA CAG GTT GC 20 50 57.3 
Gene- HER1     
Forward TCT TTC CTT CTT AAA GAC CAT CCA 24 37.5 57.6 
Reverse GTG TTG AGG GCA ATG AGG AC 20 55.0 59.4 
Gene- HER2     
Forward GGT GCA GCT GGT GAC ACA 18 61.1 58.2 
Reverse TTT TCC CGG ACA TGG TCT AA 20 45.0 55.3 
Gene- GAPDH     
Forward TCC ACT GGC GTC TTC ACC 18 61.1 58.2 











Appendix H: Crossing point values for VEGF gene expression with UPL and SYBR 















Patients     
1 33.66 25.69 38.00 33.60 
2 33.65 26.63 30.39 24.58 
3 35.16 28.91 34.16 27.47 
4 36.64 26.53 32.80 27.56 
5 34.10 27.30 32.09 26.78 
6 30.83 25.16 30.96 25.86 
7 32.16 26.53 33.57 29.14 
8 33.79 26.51 34.63 27.78 
9 36.01 30.66 30.98 25.11 
10 35.57 29.12 30.88 26.25 
11 31.28 25.83 27.95 23.72 
12 32.97 29.41 29.22 24.90 
13 28.88 24.04 27.64 24.65 
14 32.33 30.02 31.53 27.56 
15 29.53 26.25 28.31 25.06 
16 28.66 23.71 24.92 22.57 
17 28.33 24.77 28.85 26.18 
18 29.82 26.71 26.38 23.71 
19 30.34 25.58 26.80 23.65 
20 28.90 25.78 28.97 25.68 
21 27.38 24.50 29.17 29.02 
22 36.63 37.48 13.80 0.00 
23 26.89 25.94 26.10 29.30 
24 31.16 31.01 28.34 24.29 
25 28.53 27.28 27.97 26.76 
26 28.53 26.30 33.66 34.13 
27 30.33 30.79 24.61 26.31 
28 26.35 27.48 26.89 28.20 
29 27.05 26.24 28.28 29.50 








Appendix I: Histological assessment of 19 pairs of oesophageal squamous cell carcinoma 
 
Sample # Clinical Type Histological type 
1* Normal Normal epithelia, dysplastic, tumour present; MIB1 marker to show 
dysplasia (Figure 3.15. A) 
2* Tumour Pulled tissue, AE13 marker, no visible tumour 
3 Normal Normal epithelia, eosinophils present, oesophagitis 
4 Tumour Moderately differentiated tumour, keratinization 
5 Normal Normal epithelia, no tumour present 
6 Tumour Moderately differentiated tumour (70%), keratinization 
7 Normal Normal muscle, no epithelia present 
8 Tumour Moderately differentiated tumour, food particles present 
9* Normal Not good specimen, tumour present: epithelial markers AE13 (Figure 
3.16. A) 
10 Tumour Tumour present 
11* Normal Normal dysplastic epithelia, Invasive tumour present 
12 Tumour Moderately differentiated tumour 
15* Normal Normal epithelia, degenerated tissue suspicious for carcinoma 
16 Tumour Tumour present 
17 Normal Normal smooth muscle and fibrocollagenous tissue, no epithelium 
present 
18 Tumour Moderately differentiated tumour, very small amount. Foreign material 
present 
19* Normal Tumour in normal tissue. AE13 marker to confirm epithelial tissue 
20 Tumour Moderately differentiated tumour (60%) 
21 Normal Normal skeletal muscle confirmed by AE13 epithelial marker 
22 Tumour Moderately differentiated tumour 
23 Normal Normal epithelia 
24 Tumour Moderately differentiated tumour (60%), dyplastic and invasive 
27 Normal Normal epithelia 
28* Tumour Freezer artifact- degenerated tissue 
33 Normal Normal epithelia, good specimen, no tumour present 
34 Tumour Tumour present, not good enough specimen to grade differentiation 
37 Normal Skeletal & smooth muscle, fibrocollagenous tissue. No tumour present 
38 Tumour Tumour present, confirmed by marker, very little tumour (approx. 10 
cells) of poor quality 
41 Normal Skeletal muscle, AE13 marker to check for epithelial cells 
42 Tumour No visible tumour. AE13 marker to check for epithelial cells.  
43* Normal Freezer artifact- degenerated tissue 
44 Tumour Freezer artifact- degenerated tissue, some remnants of tumour (Figure 
3.16. B) 
45* Normal Normal epithelia, tumour present (Figure 3.15. B) 
46 Tumour Moderately differentiated tumour (70%) 
51 Normal Smooth muscle, no epithelia present. No tumour present 
52 Tumour Poorly differentiated tumour 
59 Normal Fibro fatty tissue 
60 Tumour Moderately differentiated tumour. many apoptotic and mitotic figures 
 








Figure J.1. Pleomorphic cells and mitotic figures present within squamous cell carcinoma of 




Figure J.2. The host lymphocytic response of squamous cell carcinoma of the oesophagus 




Figure J.3. Confluent necrosis within squamous cell carcinoma of the oesophagus (arrow) 




Figure J.4. Squamous cell carcinoma of the oesophagus presenting abundant keratinization 
and indicating, a well differentiated component (*) and peripheral moderate differentiation 





Figure J.5. Anaplasia within squamous cell carcinoma of the oesophagus (arrow) (H&E stain: 









Figure J.6. Myenteric plexus invasion by tumour cells within OSCC (arrow) (H&E stain: 




Figure J.7. Perineurial invasion by tumour cells in OSCC (arrow) (H&E stain: original 





Figure J.8. Invasion of the perineurium by tumour cells within adventitial oesophageal tissue 




Figure J.9. Normal oesophageal squamous epithelium overlying submucosal tumour 





Figure J.10. Tumour infiltration on the serosal surface of oesophageal tissue (H&E stain: 





Figure J.11. Immunohistochemical D240 stain confirming tumour cells within lymphatic 









Figure J.12. A, Surface dysplasia in OSCC with tumour infiltration of subepithelial lymphatic 
channels. B, Tumour cells within lymphatics in OSCC. C, Dysplastic epithelia of OSCC. 
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